

Potently neutralizing and protective human antibodies

Nature

584, 443-449

DOI: [10.1038/s41586-020-2548-6](https://doi.org/10.1038/s41586-020-2548-6)

Citation Report

#	ARTICLE	IF	CITATIONS
1	A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures. <i>Nature</i> , 2020, 586, 560-566.	13.7	527
2	High Potency of a Bivalent Human VH Domain in SARS-CoV-2 Animal Models. <i>Cell</i> , 2020, 183, 429-441.e16.	13.5	100
3	A Therapeutic Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model. <i>Cell</i> , 2020, 183, 1058-1069.e19.	13.5	305
5	A Minimalist Strategy Towards Temporarily Defining Protection for COVID-19. <i>SN Comprehensive Clinical Medicine</i> , 2020, 2, 2059-2066.	0.3	8
6	Structural Basis of SARS-CoV-2 and SARS-CoV Antibody Interactions. <i>Trends in Immunology</i> , 2020, 41, 1006-1022.	2.9	79
7	Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19. <i>Nature Immunology</i> , 2020, 21, 1506-1516.	7.0	563
8	Superantigenic character of an insert unique to SARS-CoV-2 spike supported by skewed TCR repertoire in patients with hyperinflammation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 25254-25262.	3.3	252
9	Profile of SARS-CoV-2. <i>Wiener Klinische Wochenschrift</i> , 2020, 132, 635-644.	1.0	4
10	The immunology of SARS-CoV-2 infections and vaccines. <i>Seminars in Immunology</i> , 2020, 50, 101422.	2.7	85
11	Cardiovascular Manifestations of COVID-19 Infection. <i>Cells</i> , 2020, 9, 2508.	1.8	142
12	Immunopathology, host-virus genome interactions, and effective vaccine development in SARS-CoV-2. <i>Computational and Structural Biotechnology Journal</i> , 2020, 18, 3774-3787.	1.9	12
13	Applying Immune Instincts and Maternal Intelligence from Comparative Microbiology to COVID-19. <i>SN Comprehensive Clinical Medicine</i> , 2020, 2, 2670-2683.	0.3	8
14	SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. <i>Nature</i> , 2020, 588, 682-687.	13.7	1,346
15	Spike Glycoprotein-Mediated Entry of SARS Coronaviruses. <i>Viruses</i> , 2020, 12, 1289.	1.5	35
16	COVID-19: The Immune Responses and Clinical Therapy Candidates. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5559.	1.8	25
17	Approaches and Challenges in SARS-CoV-2 Vaccine Development. <i>Cell Host and Microbe</i> , 2020, 28, 364-370.	5.1	98
18	Structural order in plasmonic superlattices. <i>Nature Communications</i> , 2020, 11, 3821.	5.8	56
19	Integrated pipeline for the accelerated discovery of antiviral antibody therapeutics. <i>Nature Biomedical Engineering</i> , 2020, 4, 1030-1043.	11.6	46

#	ARTICLE	IF	CITATIONS
20	Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding. <i>Cell</i> , 2020, 182, 1295-1310.e20.	13.5	1,726
21	Measuring immunity to SARS-CoV-2 infection: comparing assays and animal models. <i>Nature Reviews Immunology</i> , 2020, 20, 727-738.	10.6	107
22	Molecular Architecture of Early Dissemination and Massive Second Wave of the SARS-CoV-2 Virus in a Major Metropolitan Area. <i>MBio</i> , 2020, 11, .	1.8	99
23	Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2. <i>Cell</i> , 2020, 183, 1367-1382.e17.	13.5	420
24	Developing Antibody Defenses. <i>IEEE Pulse</i> , 2020, 11, 2-6.	0.1	0
25	The future of sepsis research: time to think differently?. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2020, 319, L523-L526.	1.3	4
26	Cell and animal models of SARS-CoV-2 pathogenesis and immunity. <i>DMM Disease Models and Mechanisms</i> , 2020, 13, .	1.2	46
27	Beyond Shielding: The Roles of Glycans in the SARS-CoV-2 Spike Protein. <i>ACS Central Science</i> , 2020, 6, 1722-1734.	5.3	727
28	Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms. <i>Science</i> , 2020, 370, 950-957.	6.0	504
29	Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 212.	7.1	104
30	Naturally activated adaptive immunity in COVID-19 patients. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 12457-12463.	1.6	21
31	Therapeutic antibodies and fusion inhibitors targeting the spike protein of SARS-CoV-2. <i>Expert Opinion on Therapeutic Targets</i> , 2021, 25, 415-421.	1.5	52
32	Coronavirus Antiviral Research Database (CoV-RDB): An Online Database Designed to Facilitate Comparisons between Candidate Anti-Coronavirus Compounds. <i>Viruses</i> , 2020, 12, 1006.	1.5	60
33	A meta-analysis of the incidence of venous thromboembolic events and impact of anticoagulation on mortality in patients with COVID-19. <i>International Journal of Infectious Diseases</i> , 2020, 100, 34-41.	1.5	58
34	Emerging antibody-based therapeutics against SARS-CoV-2 during the global pandemic. <i>Antibody Therapeutics</i> , 2020, 3, 246-256.	1.2	34
35	Will SARS-CoV-2 Infection Elicit Long-Lasting Protective or Sterilising Immunity? Implications for Vaccine Strategies (2020). <i>Frontiers in Immunology</i> , 2020, 11, 571481.	2.2	48
36	Rapid and sensitive detection of SARS-CoV-2 antibodies by biolayer interferometry. <i>Scientific Reports</i> , 2020, 10, 21738.	1.6	49
37	Neutralizing antibodies for the treatment of COVID-19. <i>Nature Biomedical Engineering</i> , 2020, 4, 1134-1139.	11.6	98

#	ARTICLE	IF	CITATIONS
38	An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike. <i>Science</i> , 2020, 370, 1473-1479.	6.0	336
39	Germline immunoglobulin genes: Disease susceptibility genes hidden in plain sight?. <i>Current Opinion in Systems Biology</i> , 2020, 24, 100-108.	1.3	31
40	Characteristics of SARS-CoV-2 and COVID-19. <i>Nature Reviews Microbiology</i> , 2021, 19, 141-154.	13.6	3,334
41	COVID-19: Discovery, diagnostics and drug development. <i>Journal of Hepatology</i> , 2021, 74, 168-184.	1.8	302
42	Evidence and speculations: vaccines and therapeutic options for COVID-19 pandemic. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 1113-1121.	1.4	4
43	Antibodies at work in the time of severe acute respiratory syndrome coronavirus 2. <i>Cytotherapy</i> , 2021, 23, 101-110.	0.3	14
44	Whither immunity? The search for effective, durable immunity to coronavirus disease 2019 (COVID-19). <i>Infection Control and Hospital Epidemiology</i> , 2021, 42, 205-207.	1.0	2
45	Generation of a cost-effective cell line for support of high-throughput isolation of primary human B cells and monoclonal neutralizing antibodies. <i>Journal of Immunological Methods</i> , 2021, 488, 112901.	0.6	9
46	Suitability of two rapid lateral flow immunochromatographic assays for predicting SARS-CoV-2 neutralizing activity of sera. <i>Journal of Medical Virology</i> , 2021, 93, 2301-2306.	2.5	12
47	SARS-CoV-2: Targeted managements and vaccine development. <i>Cytokine and Growth Factor Reviews</i> , 2021, 58, 16-29.	3.2	44
48	Venous thromboembolic events in patients with COVID-19: a systematic review and meta-analysis. <i>Age and Ageing</i> , 2021, 50, 284-293.	0.7	27
49	Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition. <i>Cell Host and Microbe</i> , 2021, 29, 44-57.e9.	5.1	937
50	Challenges and opportunities for antiviral monoclonal antibodies as COVID-19 therapy. <i>Advanced Drug Delivery Reviews</i> , 2021, 169, 100-117.	6.6	63
51	COVID-19 antibody development fueled by HIV-1 broadly neutralizing antibody research. <i>Current Opinion in HIV and AIDS</i> , 2021, 16, 25-35.	1.5	7
52	Enhanced SARS-CoV-2 neutralization by dimeric IgA. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	379
53	COVID-19: The Effect of Host Genetic Variations on Host-Virus Interactions. <i>Journal of Proteome Research</i> , 2021, 20, 139-153.	1.8	14
54	The virus that shook the world: questions and answers about SARS-CoV-2 and COVID-19. <i>Biotechnology and Biotechnological Equipment</i> , 2021, 35, 74-102.	0.5	13
55	Therapeutic and Vaccine Options for COVID-19: Status after Six Months of the Disease Outbreak. <i>SLAS Discovery</i> , 2021, 26, 311-329.	1.4	4

#	ARTICLE	IF	CITATIONS
56	The central role of the nasal microenvironment in the transmission, modulation, and clinical progression of SARS-CoV-2 infection. <i>Mucosal Immunology</i> , 2021, 14, 305-316.	2.7	173
57	Viral targets for vaccines against COVID-19. <i>Nature Reviews Immunology</i> , 2021, 21, 73-82.	10.6	832
58	Neutralizing antibodies targeting SARS-CoV-2 spike protein. <i>Stem Cell Research</i> , 2021, 50, 102125.	0.3	89
59	Ferritin as a Platform for Creating Antiviral Mosaic Nanocages: Prospects for Treating COVID-19. <i>ChemBioChem</i> , 2021, 22, 1371-1378.	1.3	2
60	Spike Glycoprotein and Host Cell Determinants of SARS-CoV-2 Entry and Cytopathic Effects. <i>Journal of Virology</i> , 2021, 95, .	1.5	70
61	Identifying and repurposing antiviral drugs against severe acute respiratory syndrome coronavirus 2 with in silico and in vitro approaches. <i>Biochemical and Biophysical Research Communications</i> , 2021, 538, 137-144.	1.0	12
62	Live unattenuated vaccines for controlling viral diseases, including COVID-19. <i>Journal of Medical Virology</i> , 2021, 93, 1943-1949.	2.5	4
64	Pathogenic Human Coronaviruses. , 2021, , .		5
65	Newcastle Disease Virus-Like Particles Displaying Prefusion-Stabilized SARS-CoV-2 Spikes Elicit Potent Neutralizing Responses. <i>Vaccines</i> , 2021, 9, 73.	2.1	24
66	Development of a Fast SARS-CoV-2 IgG ELISA, Based on Receptor-Binding Domain, and Its Comparative Evaluation Using Temporally Segregated Samples From RT-PCR Positive Individuals. <i>Frontiers in Microbiology</i> , 2020, 11, 618097.	1.5	30
67	Inhibition of SARS-CoV-2 pseudovirus invasion by ACE2 protecting and Spike neutralizing peptides: An alternative approach to COVID19 prevention and therapy. <i>International Journal of Biological Sciences</i> , 2021, 17, 2957-2969.	2.6	11
68	SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice. <i>Nature Communications</i> , 2021, 12, 372.	5.8	369
70	Molecular determinants and mechanism for antibody cocktail preventing SARS-CoV-2 escape. <i>Nature Communications</i> , 2021, 12, 469.	5.8	148
71	COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 905-919.	1.3	445
75	More Than Just Gene Therapy Vectors: Lentiviral Vector Pseudotypes for Serological Investigation. <i>Viruses</i> , 2021, 13, 217.	1.5	13
76	One-Year Sustained Cellular and Humoral Immunities in Coronavirus Disease 2019 (COVID-19) Convalescents. <i>Clinical Infectious Diseases</i> , 2022, 75, e1072-e1081.	2.9	48
77	Evolution of antibody immunity to SARS-CoV-2. <i>Nature</i> , 2021, 591, 639-644.	13.7	1,355
78	Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications. <i>Journal of Biomedical Science</i> , 2021, 28, 9.	2.6	167

#	ARTICLE	IF	CITATIONS
80	Passive Immunity Should and Will Work for COVID-19 for Some Patients. <i>Clinical Hematology International</i> , 2021, 3, 47.	0.7	4
82	Differential and sequential immunomodulatory role of neutrophils and Ly6C ^{hi} inflammatory monocytes during antiviral antibody therapy. <i>Emerging Microbes and Infections</i> , 2021, 10, 964-981.	3.0	3
83	A human cell-based SARS-CoV-2 vaccine elicits potent neutralizing antibody responses and protects mice from SARS-CoV-2 challenge. <i>Emerging Microbes and Infections</i> , 2021, 10, 1555-1573.	3.0	6
84	Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections. <i>Nature Communications</i> , 2021, 12, 264.	5.8	81
86	Inference of SARS-CoV-2 spike-binding neutralizing antibody titers in sera from hospitalized COVID-19 patients by using commercial enzyme and chemiluminescent immunoassays. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 485-494.	1.3	37
87	Overview of Nonhuman Primate Models of SARS-CoV-2 Infection. <i>Comparative Medicine</i> , 2021, 71, 411-432.	0.4	11
88	SARS-CoV-2 specific antibody and neutralization assays reveal the wide range of the humoral immune response to virus. <i>Communications Biology</i> , 2021, 4, 129.	2.0	95
89	Structural Analysis of Neutralizing Epitopes of the SARS-CoV-2 Spike to Guide Therapy and Vaccine Design Strategies. <i>Viruses</i> , 2021, 13, 134.	1.5	56
90	Effective virus-neutralizing activities in antisera from the first wave of severe COVID-19 survivors. <i>JCI Insight</i> , 2021, 6, .	2.3	10
92	Dual-Antigen System Allows Elimination of False Positive Results in COVID-19 Serological Testing. <i>Diagnostics</i> , 2021, 11, 102.	1.3	8
93	Development of potent and effective synthetic SARS-CoV-2 neutralizing nanobodies. <i>MAbs</i> , 2021, 13, 1958663.	2.6	16
94	Standardized Two-Step Testing of Antibody Activity in COVID-19 Convalescent Plasma. <i>SSRN Electronic Journal</i> , 0, .	0.4	2
98	Epitope-resolved profiling of the SARS-CoV-2 antibody response identifies cross-reactivity with endemic human coronaviruses. <i>Cell Reports Medicine</i> , 2021, 2, 100189.	3.3	149
101	Spike S2 Subunit: The Dark Horse in the Race for Prophylactic and Therapeutic Interventions against SARS-CoV-2. <i>Vaccines</i> , 2021, 9, 178.	2.1	23
103	A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2. <i>Nature Communications</i> , 2021, 12, 776.	5.8	65
104	Clinical correlates of anti-SARS-CoV-2 antibody profiles in Spanish COVID-19 patients from a high incidence region. <i>Scientific Reports</i> , 2021, 11, 4363.	1.6	9
106	Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. <i>Science</i> , 2021, 371, .	6.0	2,268
108	COVID-19 Antibody Tests and Their Limitations. <i>ACS Sensors</i> , 2021, 6, 593-612.	4.0	150

#	ARTICLE	IF	CITATIONS
111	Single-domain antibodies make a difference. <i>Science</i> , 2021, 371, 681-682.	6.0	12
113	Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice. <i>Science</i> , 2021, 371, 735-741.	6.0	305
114	Post-exposure protection of SARS-CoV-2 lethal infected K18-hACE2 transgenic mice by neutralizing human monoclonal antibody. <i>Nature Communications</i> , 2021, 12, 944.	5.8	53
115	In silico analysis suggests less effective MHC-II presentation of SARS-CoV-2 RBM peptides: Implication for neutralizing antibody responses. <i>PLoS ONE</i> , 2021, 16, e0246731.	1.1	7
116	Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD. <i>Cell Reports</i> , 2021, 34, 108699.	2.9	110
117	SARS-CoV-2 mRNA Vaccines: Immunological Mechanism and Beyond. <i>Vaccines</i> , 2021, 9, 147.	2.1	175
118	mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. <i>Nature</i> , 2021, 592, 616-622.	13.7	1,232
122	Identification of HLA-A*02:01-Restricted Candidate Epitopes Derived from the Nonstructural Polyprotein 1a of SARS-CoV-2 That May Be Natural Targets of CD8 ⁺ T Cell Recognition <i>In Vivo</i> . <i>Journal of Virology</i> , 2021, 95, .	1.5	20
123	Clinical, laboratory, and temporal predictors of neutralizing antibodies against SARS-CoV-2 among COVID-19 convalescent plasma donor candidates. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	72
124	Antibody titers against SARS-CoV-2 decline, but do not disappear for several months. <i>EClinicalMedicine</i> , 2021, 32, 100734.	3.2	134
125	Determining available strategies for prevention and therapy: Exploring COVID-19 from the perspective of ACE2 (Review). <i>International Journal of Molecular Medicine</i> , 2021, 47, .	1.8	8
130	A longitudinal study of convalescent plasma (CCP) donors and correlation of ABO group, initial neutralizing antibodies (nAb), and body mass index (BMI) with nAb and anti-nucleocapsid (NP) SARS-CoV-2 antibody kinetics: Proposals for better quality of CCP collections. <i>Transfusion</i> , 2021, 61, 1447-1460.	0.8	22
132	Adaptive immunity to SARS-CoV-2 and COVID-19. <i>Cell</i> , 2021, 184, 861-880.	13.5	1,364
133	SARS-CoV-2 Proteome-Wide Analysis Revealed Significant Epitope Signatures in COVID-19 Patients. <i>Frontiers in Immunology</i> , 2021, 12, 629185.	2.2	42
135	Diagnostic Value of IgM and IgG Detection in COVID-19 Diagnosis by the Mobile Laboratory B-LiFE: A Massive Testing Strategy in the Piedmont Region. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 3372.	1.2	3
136	SARS-CoV-2-induced humoral immunity through B cell epitope analysis in COVID-19 infected individuals. <i>Scientific Reports</i> , 2021, 11, 5934.	1.6	26
142	Neutralization of SARS-CoV-2 with IgG from COVID-19-convalescent plasma. <i>Scientific Reports</i> , 2021, 11, 5563.	1.6	42
143	Nicotinic cholinergic system and COVID-19: In silico identification of interactions between $\alpha 7$ nicotinic acetylcholine receptor and the cryptic epitopes of SARS-CoV and SARS-CoV-2 Spike glycoproteins. <i>Food and Chemical Toxicology</i> , 2021, 149, 112009.	1.8	46

#	ARTICLE	IF	CITATIONS
144	Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. <i>Nature Medicine</i> , 2021, 27, 717-726.	15.2	838
145	Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. <i>Cell Host and Microbe</i> , 2021, 29, 463-476.e6.	5.1	1,054
146	A Rapid and Efficient Screening System for Neutralizing Antibodies and Its Application for SARS-CoV-2. <i>Frontiers in Immunology</i> , 2021, 12, 653189.	2.2	20
148	Approaching the Interpretation of Discordances in SARS-CoV-2 Testing. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab144.	0.4	2
151	mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. <i>Science</i> , 2021, 372, 1413-1418.	6.0	468
152	Neutralizing Monoclonal Anti-SARS-CoV-2 Antibodies Isolated from Immunized Rabbits Define Novel Vulnerable Spike-Protein Epitope. <i>Viruses</i> , 2021, 13, 566.	1.5	23
153	Comparison of Subgenomic and Total RNA in SARS-CoV-2-Challenged Rhesus Macaques. <i>Journal of Virology</i> , 2021, 95, .	1.5	87
154	Monoclonal antibodies capable of binding SARS-CoV-2 spike protein receptor-binding motif specifically prevent GM-CSF induction. <i>Journal of Leukocyte Biology</i> , 2021, 111, 261-267.	1.5	13
155	Correlates of Vaccine-Induced Protection against SARS-CoV-2. <i>Vaccines</i> , 2021, 9, 238.	2.1	49
156	Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. <i>Cell Host and Microbe</i> , 2021, 29, 477-488.e4.	5.1	700
158	A proof of concept for neutralizing antibody-guided vaccine design against SARS-CoV-2. <i>National Science Review</i> , 2021, 8, nwab053.	4.6	36
159	COVID-19 vaccines: The status and perspectives in delivery points of view. <i>Advanced Drug Delivery Reviews</i> , 2021, 170, 1-25.	6.6	262
160	Drug discovery and development targeting the life cycle of SARS-CoV-2. <i>Fundamental Research</i> , 2021, 1, 151-165.	1.6	9
161	Therapeutic activity of an inhaled potent SARS-CoV-2 neutralizing human monoclonal antibody in hamsters. <i>Cell Reports Medicine</i> , 2021, 2, 100218.	3.3	57
162	Immunogenicity of prime-boost protein subunit vaccine strategies against SARS-CoV-2 in mice and macaques. <i>Nature Communications</i> , 2021, 12, 1403.	5.8	65
163	Antibody isotype diversity against SARS-CoV-2 is associated with differential serum neutralization capacities. <i>Scientific Reports</i> , 2021, 11, 5538.	1.6	37
166	Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. <i>Nature</i> , 2021, 593, 130-135.	13.7	1,904
168	Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	109

#	ARTICLE	IF	CITATIONS
173	Enhancing the Prefusion Conformational Stability of SARS-CoV-2 Spike Protein Through Structure-Guided Design. <i>Frontiers in Immunology</i> , 2021, 12, 660198.	2.2	28
174	Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived antibody class. <i>Cell Reports</i> , 2021, 35, 108950.	2.9	54
175	Coronavirus disease 2019 and the revival of passive immunization: Antibody therapy for inhibiting severe acute respiratory syndrome coronavirus 2 and preventing host cell infection: IUPHAR review 31. <i>British Journal of Pharmacology</i> , 2021, 178, 3359-3372.	2.7	10
176	Robust SARS-CoV-2 infection in nasal turbinates after treatment with systemic neutralizing antibodies. <i>Cell Host and Microbe</i> , 2021, 29, 551-563.e5.	5.1	87
177	The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	347
178	Extremely potent human monoclonal antibodies from COVID-19 convalescent patients. <i>Cell</i> , 2021, 184, 1821-1835.e16.	13.5	180
179	SARS-CoV-2 can recruit a heme metabolite to evade antibody immunity. <i>Science Advances</i> , 2021, 7, .	4.7	107
182	Native-like SARS-CoV-2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222 Vaccine. <i>ACS Central Science</i> , 2021, 7, 594-602.	5.3	118
183	IgG and IgM antibody formation to spike and nucleocapsid proteins in COVID-19 characterized by multiplex immunoblot assays. <i>BMC Infectious Diseases</i> , 2021, 21, 325.	1.3	26
184	Neutralizing Antibody Therapeutics for COVID-19. <i>Viruses</i> , 2021, 13, 628.	1.5	99
185	A real-time and high-throughput neutralization test based on SARS-CoV-2 pseudovirus containing monomeric infrared fluorescent protein as reporter. <i>Emerging Microbes and Infections</i> , 2021, 10, 894-904.	3.0	16
187	Considerations for bioanalytical characterization and batch release of COVID-19 vaccines. <i>Npj Vaccines</i> , 2021, 6, 53.	2.9	23
188	Safe and effective two-in-one replicon-and-VLP minispikes vaccine for COVID-19: Protection of mice after a single immunization. <i>PLoS Pathogens</i> , 2021, 17, e1009064.	2.1	21
189	Impact of the N501Y substitution of SARS-CoV-2 Spike on neutralizing monoclonal antibodies targeting diverse epitopes. <i>Virology Journal</i> , 2021, 18, 87.	1.4	27
190	Multifunctional angiotensin converting enzyme 2, the SARS-CoV-2 entry receptor, and critical appraisal of its role in acute lung injury. <i>Biomedicine and Pharmacotherapy</i> , 2021, 136, 111193.	2.5	42
192	Bridging animal and clinical research during SARS-CoV-2 pandemic: A new-old challenge. <i>EBioMedicine</i> , 2021, 66, 103291.	2.7	15
193	The antigenic anatomy of SARS-CoV-2 receptor binding domain. <i>Cell</i> , 2021, 184, 2183-2200.e22.	13.5	331
194	A multiplex antigen microarray for simultaneous IgG and IgM detection against SARS-CoV-2 reveals higher seroprevalence than reported. <i>Microbial Biotechnology</i> , 2021, 14, 1228-1236.	2.0	11

#	ARTICLE	IF	CITATIONS
195	Antibody Therapy: From Diphtheria to Cancer, COVID-19, and Beyond. <i>Monoclonal Antibodies in Immunodiagnosis and Immunotherapy</i> , 2021, 40, 36-49.	0.8	8
196	Antibody Affinity Governs the Inhibition of SARS-CoV-2 Spike/ACE2 Binding in Patient Serum. <i>ACS Infectious Diseases</i> , 2021, 7, 2362-2369.	1.8	32
197	Convergence of a common solution for broad ebolavirus neutralization by glycan cap-directed human antibodies. <i>Cell Reports</i> , 2021, 35, 108984.	2.9	22
199	Antibodies and Vaccines Target RBD of SARS-CoV-2. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 671633.	1.6	108
200	N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. <i>Cell</i> , 2021, 184, 2332-2347.e16.	13.5	784
201	Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein. <i>Cell</i> , 2021, 184, 2316-2331.e15.	13.5	321
202	Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection. <i>Cell</i> , 2021, 184, 1804-1820.e16.	13.5	297
203	Integrative overview of antibodies against SARS-CoV-2 and their possible applications in COVID-19 prophylaxis and treatment. <i>Microbial Cell Factories</i> , 2021, 20, 88.	1.9	37
204	Concerns about SARS-CoV-2 evolution should not hold back efforts to expand vaccination. <i>Nature Reviews Immunology</i> , 2021, 21, 330-335.	10.6	98
205	Durable SARS-CoV-2 B cell immunity after mild or severe disease. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	76
206	A human coronavirus evolves antigenically to escape antibody immunity. <i>PLoS Pathogens</i> , 2021, 17, e1009453.	2.1	183
207	Computational epitope map of SARS-CoV-2 spike protein. <i>PLoS Computational Biology</i> , 2021, 17, e1008790.	1.5	109
209	Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016. <i>Cell Reports Medicine</i> , 2021, 2, 100255.	3.3	402
212	Genome-Wide B Cell, CD4+, and CD8+ T Cell Epitopes That Are Highly Conserved between Human and Animal Coronaviruses, Identified from SARS-CoV-2 as Targets for Preemptive Pan-Coronavirus Vaccines. <i>Journal of Immunology</i> , 2021, 206, 2566-2582.	0.4	53
213	Comparative Perturbation-Based Modeling of the SARS-CoV-2 Spike Protein Binding with Host Receptor and Neutralizing Antibodies: Structurally Adaptable Allosteric Communication Hotspots Define Spike Sites Targeted by Global Circulating Mutations. <i>Biochemistry</i> , 2021, 60, 1459-1484.	1.2	62
217	Lipid Nanoparticle RBD-hFc mRNA Vaccine Protects hACE2 Transgenic Mice against a Lethal SARS-CoV-2 Infection. <i>Nano Letters</i> , 2021, 21, 4774-4779.	4.5	20
220	Advancing HIV Broadly Neutralizing Antibodies: From Discovery to the Clinic. <i>Frontiers in Public Health</i> , 2021, 9, 690017.	1.3	26
221	Kinetics of Neutralizing Antibodies of COVID-19 Patients Tested Using Clinical D614G, B.1.1.7, and B.1.351 Isolates in Microneutralization Assays. <i>Viruses</i> , 2021, 13, 996.	1.5	14

#	ARTICLE	IF	CITATIONS
222	Possible inhibition of GM-CSF production by SARS-CoV-2 spike-based vaccines. <i>Molecular Medicine</i> , 2021, 27, 49.	1.9	7
223	Inhalable Nanobody (PiN-21) prevents and treats SARS-CoV-2 infections in Syrian hamsters at ultra-low doses. <i>Science Advances</i> , 2021, 7, .	4.7	113
224	Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes. <i>Science</i> , 2021, 372, 1108-1112.	6.0	210
225	Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses. <i>Nature</i> , 2021, 594, 553-559.	13.7	199
226	IgV somatic mutation of human anti-“SARS-CoV-2 monoclonal antibodies governs neutralization and breadth of reactivity. <i>JCI Insight</i> , 2021, 6, .	2.3	13
227	Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization. <i>Cell Host and Microbe</i> , 2021, 29, 747-751.e4.	5.1	504
228	High-resolution profiling of pathways of escape for SARS-CoV-2 spike-binding antibodies. <i>Cell</i> , 2021, 184, 2927-2938.e11.	13.5	35
229	Adaptive immune responses to SARS-CoV-2. <i>Advanced Drug Delivery Reviews</i> , 2021, 172, 1-8.	6.6	6
230	A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection. <i>Cell Host and Microbe</i> , 2021, 29, 806-818.e6.	5.1	49
231	Outpatient Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 Infection to Prevent Coronavirus Disease 2019 Progression. <i>Clinical Infectious Diseases</i> , 2021, 73, 1717-1721.	2.9	16
232	Requirement of Fc-Fc Gamma Receptor Interaction for Antibody-Based Protection against Emerging Virus Infections. <i>Viruses</i> , 2021, 13, 1037.	1.5	20
234	Mapping the SARS-CoV-2 spike glycoprotein-derived peptidome presented by HLA class II on dendritic cells. <i>Cell Reports</i> , 2021, 35, 109179.	2.9	63
236	A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes. <i>Nature Communications</i> , 2021, 12, 2623.	5.8	64
237	Antibody evasion by the P.1 strain of SARS-CoV-2. <i>Cell</i> , 2021, 184, 2939-2954.e9.	13.5	519
238	SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?. <i>Advanced Drug Delivery Reviews</i> , 2021, 172, 314-338.	6.6	75
239	Evaluation of Cellular and Serological Responses to Acute SARS-CoV-2 Infection Demonstrates the Functional Importance of the Receptor-Binding Domain. <i>Journal of Immunology</i> , 2021, 206, 2605-2613.	0.4	7
241	Insights into forsythia honeysuckle (Lianhuaqingwen) capsules: A Chinese herbal medicine repurposed for COVID-19 pandemic. <i>Phytomedicine Plus</i> , 2021, 1, 100027.	0.9	23
243	Detection of Anti-Nucleocapsid Antibody in COVID-19 Patients in Bangladesh Is not Correlated with Previous Dengue Infection. <i>Pathogens</i> , 2021, 10, 637.	1.2	5

#	ARTICLE	IF	CITATIONS
244	Aptamer BC 007â€™s Affinity to Specific and Less-Specific Anti-SARS-CoV-2 Neutralizing Antibodies. <i>Viruses</i> , 2021, 13, 932.	1.5	5
245	Structural basis for broad coronavirus neutralization. <i>Nature Structural and Molecular Biology</i> , 2021, 28, 478-486.	3.6	152
247	SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19. <i>The Cochrane Library</i> , 0, , .	1.5	2
248	Blueprint for pandemic response: Focus on translational medicine, clinical pharmacology and pharmacometrics. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 3398-3407.	1.1	1
249	Diverse immunoglobulin gene usage and convergent epitope targeting in neutralizing antibody responses to SARS-CoV-2. <i>Cell Reports</i> , 2021, 35, 109109.	2.9	21
250	Prospects of Neutralizing Nanobodies Against SARS-CoV-2. <i>Frontiers in Immunology</i> , 2021, 12, 690742.	2.2	22
251	On the road to ending the COVID-19 pandemic: Are we there yet?. <i>Virology</i> , 2021, 557, 70-85.	1.1	38
252	Structural insights into the cross-neutralization of SARS-CoV and SARS-CoV-2 by the human monoclonal antibody 47D11. <i>Science Advances</i> , 2021, 7, .	4.7	42
253	A SARS-CoV-2 antibody curbs viral nucleocapsid protein-induced complement hyperactivation. <i>Nature Communications</i> , 2021, 12, 2697.	5.8	61
254	A review of monoclonal antibodies in COVID-19: Role in immunotherapy, vaccine development and viral detection. <i>Human Antibodies</i> , 2021, 29, 1-13.	0.6	20
256	Humoral Immunity against SARS-CoV-2 and the Impact on COVID-19 Pathogenesis. <i>Molecules and Cells</i> , 2021, 44, 392-400.	1.0	22
257	Multivalency transforms SARS-CoV-2 antibodies into ultrapotent neutralizers. <i>Nature Communications</i> , 2021, 12, 3661.	5.8	48
258	Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	198
261	The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody. <i>PLoS ONE</i> , 2021, 16, e0253487.	1.1	76
262	Extracellular vesicles carry SARSâ€™CoVâ€™2 spike protein and serve as decoys for neutralizing antibodies. <i>Journal of Extracellular Vesicles</i> , 2021, 10, e12112.	5.5	44
264	Advances in Neutralization Assays for SARSâ€™CoVâ€™2. <i>Scandinavian Journal of Immunology</i> , 2021, 94, e13088.	1.3	40
265	Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant. <i>Immunity</i> , 2021, 54, 1276-1289.e6.	6.6	112
266	Cross-Reactive SARS-CoV-2 Neutralizing Antibodies From Deep Mining of Early Patient Responses. <i>Frontiers in Immunology</i> , 2021, 12, 678570.	2.2	16

#	ARTICLE	IF	CITATIONS
267	Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 233.	7.1	203
269	Animal models for SARS-CoV-2. <i>Current Opinion in Virology</i> , 2021, 48, 73-81.	2.6	52
270	Characterization of Immune Responses to SARS-CoV-2 and Other Human Pathogenic Coronaviruses Using a Multiplex Bead-Based Immunoassay. <i>Vaccines</i> , 2021, 9, 611.	2.1	5
271	Engineering mesenchymal stromal cells with neutralizing and anti-inflammatory capability against SARS-CoV-2 infection. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021, 21, 754-764.	1.8	5
273	Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	64
274	Tackling COVID-19 with neutralizing monoclonal antibodies. <i>Cell</i> , 2021, 184, 3086-3108.	13.5	309
275	SARS-CoV-2 Antiviral Therapy. <i>Clinical Microbiology Reviews</i> , 2021, 34, e0010921.	5.7	64
276	Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants. <i>Science</i> , 2021, 373, .	6.0	174
278	Adaptation of the MTT assay for detection of neutralizing antibodies against the SARS-CoV-2 virus. <i>Zhurnal Mikrobiologii Epidemiologii I Immunobiologii</i> , 2021, 98, 253-265.	0.3	10
279	SARS-CoV-2 Neutralizing Antibody Responses towards Full-Length Spike Protein and the Receptor-Binding Domain. <i>Journal of Immunology</i> , 2021, 207, 878-887.	0.4	30
280	Screening of potent neutralizing antibodies against SARS-CoV-2 using convalescent patients-derived phage-display libraries. <i>Cell Discovery</i> , 2021, 7, 57.	3.1	28
281	Neutralizing Antibody Responses After SARS-CoV-2 Infection in End-Stage Kidney Disease and Protection Against Reinfection. <i>Kidney International Reports</i> , 2021, 6, 1799-1809.	0.4	13
282	Early treatment with a combination of two potent neutralizing antibodies improves clinical outcomes and reduces virus replication and lung inflammation in SARS-CoV-2 infected macaques. <i>PLoS Pathogens</i> , 2021, 17, e1009688.	2.1	16
283	Reprogrammed CRISPR-Cas13b suppresses SARS-CoV-2 replication and circumvents its mutational escape through mismatch tolerance. <i>Nature Communications</i> , 2021, 12, 4270.	5.8	37
284	Therapeutic antibodies under development for SARS-CoV-2. <i>View</i> , 2021, , 20200178.	2.7	4
285	A novel mouse AAV6 hACE2 transduction model of wild-type SARS-CoV-2 infection studied using synDNA immunogens. <i>Science</i> , 2021, 24, 102699.	1.9	15
287	kinetics of anti-SARS-CoV-2 antibodies over time. Results of 10 month follow up in over 300 seropositive Health Care Workers. <i>European Journal of Internal Medicine</i> , 2021, 89, 97-103.	1.0	26
288	Role of Laboratory Medicine in SARS-CoV-2 Diagnostics. Lessons Learned from a Pandemic. <i>Healthcare (Switzerland)</i> , 2021, 9, 915.	1.0	5

#	ARTICLE	IF	CITATIONS
290	Antibody and B cell responses to SARS-CoV-2 infection and vaccination. <i>Cell Host and Microbe</i> , 2021, 29, 1063-1075.	5.1	99
291	Polymersomes Decorated with the SARS-CoV-2 Spike Protein Receptor-Binding Domain Elicit Robust Humoral and Cellular Immunity. <i>ACS Central Science</i> , 2021, 7, 1368-1380.	5.3	21
292	Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies. <i>Nature Communications</i> , 2021, 12, 4196.	5.8	332
293	SARS-CoV-2 RBD-Tetanus Toxoid Conjugate Vaccine Induces a Strong Neutralizing Immunity in Preclinical Studies. <i>ACS Chemical Biology</i> , 2021, 16, 1223-1233.	1.6	57
294	Identification of Novel Neutralizing Monoclonal Antibodies against SARS-CoV-2 Spike Glycoprotein. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 1349-1361.	2.5	3
295	Cross-reactive antibodies against human coronaviruses and the animal coronavirome suggest diagnostics for future zoonotic spillovers. <i>Science Immunology</i> , 2021, 6, .	5.6	26
297	Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects. <i>Cell Reports</i> , 2021, 36, 109353.	2.9	95
298	Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	56
299	Antibody Mediated Immunity to SARS-CoV-2 and Human Coronaviruses: Multiplex Beads Assay and Volumetric Absorptive Microsampling to Generate Immune Repertoire Cartography. <i>Frontiers in Immunology</i> , 2021, 12, 696370.	2.2	14
300	Dynamic Characteristic Analysis of Antibodies in Patients With COVID-19: A 13-Month Study. <i>Frontiers in Immunology</i> , 2021, 12, 708184.	2.2	19
301	Immunogenicity and Protective Efficacy of a Highly Thermotolerant, Trimeric SARS-CoV-2 Receptor Binding Domain Derivative. <i>ACS Infectious Diseases</i> , 2021, 7, 2546-2564.	1.8	34
303	Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice. <i>Cell Reports</i> , 2021, 36, 109450.	2.9	38
304	Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells. <i>Cell Reports Medicine</i> , 2021, 2, 100354.	3.3	316
305	Potent and protective IGHV3-53/3-66 public antibodies and their shared escape mutant on the spike of SARS-CoV-2. <i>Nature Communications</i> , 2021, 12, 4210.	5.8	82
308	Rapid Generation of Coronaviral Immunity Using Recombinant Peptide Modified Nanodiamonds. <i>Pathogens</i> , 2021, 10, 861.	1.2	10
309	Identification of HLA-A2 restricted CD8+ T cell epitopes in SARS-CoV-2 structural proteins. <i>Journal of Leukocyte Biology</i> , 2021, 110, 1171-1180.	1.5	11
310	Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species. <i>Immunity</i> , 2021, 54, 1611-1621.e5.	6.6	190
311	SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape. <i>Nature</i> , 2021, 597, 97-102.	13.7	385

#	ARTICLE	IF	CITATIONS
312	Systematic analysis of SARS-CoV-2 infection of an ACE2-negative human airway cell. <i>Cell Reports</i> , 2021, 36, 109364.	2.9	109
313	Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action. <i>Npj Vaccines</i> , 2021, 6, 104.	2.9	241
314	Sex Disparities and Neutralizing-Antibody Durability to SARS-CoV-2 Infection in Convalescent Individuals. <i>MSphere</i> , 2021, 6, e0027521.	1.3	36
315	Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals. <i>Cell Reports</i> , 2021, 36, 109604.	2.9	67
316	InÂvitro and inÂvivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies. <i>Cell</i> , 2021, 184, 4203-4219.e32.	13.5	228
317	SARS-CoV-2 Neutralizing Antibodies for COVID-19 Prevention and Treatment. <i>Annual Review of Medicine</i> , 2022, 73, 1-16.	5.0	91
318	Multiple immune function impairments in diabetic patients and their effects on COVID-19. <i>World Journal of Clinical Cases</i> , 2021, 9, 6969-6978.	0.3	8
321	Antibody Response to SARS-CoV-2 Membrane Protein in Patients of the Acute and Convalescent Phase of COVID-19. <i>Frontiers in Immunology</i> , 2021, 12, 679841.	2.2	28
322	Diffuse C4d staining of peritubular capillaries in renal allograft following bamlanivimab therapy. <i>American Journal of Transplantation</i> , 2022, 22, 289-293.	2.6	3
324	Safety, Virologic Efficacy, and Pharmacokinetics of CT-P59, a Neutralizing Monoclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Protein: Two Randomized, Placebo-Controlled, Phase I Studies in Healthy Individuals and Patients With Mild SARS-CoV-2 Infection. <i>Clinical Therapeutics</i> , 2021, 43, 1706-1727.	1.1	39
325	Therapeutic alphavirus cross-reactive E1 human antibodies inhibit viral egress. <i>Cell</i> , 2021, 184, 4430-4446.e22.	13.5	25
326	SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	251
327	Single-Dose Intranasal Administration of AdCOVID Elicits Systemic and Mucosal Immunity against SARS-CoV-2 and Fully Protects Mice from Lethal Challenge. <i>Vaccines</i> , 2021, 9, 881.	2.1	86
328	â€œMolecular Masksâ€-for ACE2 to Effectively and Safely Block SARS-CoV-2 Virus Entry. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8963.	1.8	7
329	Signatures in SARS-CoV-2 spike protein conferring escape to neutralizing antibodies. <i>PLoS Pathogens</i> , 2021, 17, e1009772.	2.1	74
330	A potently neutralizing SARS-CoV-2 antibody inhibits variants of concern by utilizing unique binding residues in a highly conserved epitope. <i>Immunity</i> , 2021, 54, 2399-2416.e6.	6.6	79
331	Cooperativity mediated by rationally selected combinations of human monoclonal antibodies targeting the henipavirus receptor binding protein. <i>Cell Reports</i> , 2021, 36, 109628.	2.9	23
332	Correlation between a quantitative antiâ€\$SARSâ€CoVâ€2 IgG ELISA and neutralization activity. <i>Journal of Medical Virology</i> , 2022, 94, 388-392.	2.5	89

#	ARTICLE	IF	CITATIONS
333	A monoclonal antibody against staphylococcal enterotoxin B superantigen inhibits SARS-CoV-2 entry in vitro. <i>Structure</i> , 2021, 29, 951-962.e3.	1.6	28
334	A vaccine-induced public antibody protects against SARS-CoV-2 and emerging variants. <i>Immunity</i> , 2021, 54, 2159-2166.e6.	6.6	52
335	A surrogate cell-based SARS-CoV-2 spike blocking assay. <i>European Journal of Immunology</i> , 2021, 51, 2665-2676.	1.6	3
336	Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies. <i>Cell Reports</i> , 2021, 36, 109760.	2.9	80
337	IgG Antibodies Develop to Spike but Not to the Nucleocapsid Viral Protein in Many Asymptomatic and Light COVID-19 Cases. <i>Viruses</i> , 2021, 13, 1945.	1.5	16
338	Safety and Tolerability of the Adeno-Associated Virus Vector, AAV6.2FF, Expressing a Monoclonal Antibody in Murine and Ovine Animal Models. <i>Biomedicines</i> , 2021, 9, 1186.	1.4	7
339	A SARS-CoV-2 Neutralization Assay using Single Molecule Arrays. <i>Angewandte Chemie</i> , 0, , .	1.6	5
340	Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern. <i>Science Translational Medicine</i> , 2021, 13, eabj5413.	5.8	79
341	An ultrapotent pan- β -coronavirus lineage B (β -CoV-B) neutralizing antibody locks the receptor-binding domain in closed conformation by targeting its conserved epitope. <i>Protein and Cell</i> , 2022, 13, 655-675.	4.8	25
342	What we know and still ignore on COVID-19 immune pathogenesis and a proposal based on the experience of allergic disorders. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 1114-1128.	2.7	6
344	Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy. <i>Immunity</i> , 2021, 54, 2143-2158.e15.	6.6	155
346	Treatment and prevention strategies for the COVID 19 pandemic: A review of immunotherapeutic approaches for neutralizing SARS-CoV-2. <i>International Journal of Biological Macromolecules</i> , 2021, 186, 490-500.	3.6	28
347	Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail. <i>Nature Microbiology</i> , 2021, 6, 1233-1244.	5.9	237
348	Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study. <i>Science</i> , 2021, 374, 472-478.	6.0	228
349	SARS-CoV-2 mRNA Vaccines Elicit Different Responses in Immunologically Naïve and Pre-Immune Humans. <i>Frontiers in Immunology</i> , 2021, 12, 728021.	2.2	20
351	Neutralizing antibodies for the prevention and treatment of COVID-19. <i>Cellular and Molecular Immunology</i> , 2021, 18, 2293-2306.	4.8	91
352	A non-RBM targeted RBD specific antibody neutralizes SARS-CoV-2 inducing S1 shedding. <i>Biochemical and Biophysical Research Communications</i> , 2021, 571, 152-158.	1.0	5
353	Neutralizing antibody responses following natural SARS-CoV-2 infection: Dynamics and correlation with commercial serologic tests. <i>Journal of Clinical Virology</i> , 2021, 144, 104988.	1.6	31

#	ARTICLE	IF	CITATIONS
355	SARS-CoV-2 Subgenomic RNAs: Characterization, Utility, and Perspectives. <i>Viruses</i> , 2021, 13, 1923.	1.5	38
357	SARS-CoV-2 neutralizing antibodies decline over one year and patients with severe COVID-19 pneumonia display a unique cytokine profile. <i>International Journal of Infectious Diseases</i> , 2021, 112, 227-234.	1.5	13
358	Cross-neutralization of SARS-CoV-2 by HIV-1 specific broadly neutralizing antibodies and polyclonal plasma. <i>PLoS Pathogens</i> , 2021, 17, e1009958.	2.1	20
359	Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain. <i>Cell Reports</i> , 2021, 37, 109822.	2.9	35
360	A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19. <i>Nature Communications</i> , 2021, 12, 5469.	5.8	102
361	Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines. <i>Cell</i> , 2021, 184, 5432-5447.e16.	13.5	131
362	Dynamics of morbidity of the population with respiratory diseases in the pandemic COVID-19 period in the Far Eastern Federal District. <i>Bulletin Physiology and Pathology of Respiration</i> , 2021, , 19-26.	0.0	0
363	SARS-CoV-2, COVID-19 and the aging immune system. <i>Nature Aging</i> , 2021, 1, 769-782.	5.3	208
365	Antibody Response against SARS-CoV-2 Infection: Implications for Diagnosis, Treatment and Vaccine Development. <i>International Reviews of Immunology</i> , 2022, 41, 393-413.	1.5	13
366	A SARS-CoV-2 Neutralization Assay Using Single Molecule Arrays. <i>Angewandte Chemie - International Edition</i> , 2021, 60, 25966-25972.	7.2	21
367	Generation of potent cellular and humoral immunity against SARS-CoV-2 antigens via conjugation to a polymeric glyco-adjuvant. <i>Biomaterials</i> , 2021, 278, 121159.	5.7	23
368	Magnetofluidic immuno-PCR for point-of-care COVID-19 serological testing. <i>Biosensors and Bioelectronics</i> , 2022, 195, 113656.	5.3	18
369	SARS-CoV-2 Cellular Infection and Therapeutic Opportunities: Lessons Learned from Ebola Virus. <i>Membranes</i> , 2021, 11, 64.	1.4	0
372	Pharmacotherapeutics of SARS-CoV-2 Infections. <i>Journal of NeuroImmune Pharmacology</i> , 2021, 16, 12-37.	2.1	4
373	SARS-CoV-2 B cell receptor signatures in at-risk populations. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	0
375	Development and application of therapeutic antibodies against COVID-19. <i>International Journal of Biological Sciences</i> , 2021, 17, 1486-1496.	2.6	47
376	Potent mouse monoclonal antibodies that block SARS-CoV-2 infection. <i>Journal of Biological Chemistry</i> , 2021, 296, 100346.	1.6	15
377	Neutralizing antibody titres in SARS-CoV-2 infections. <i>Nature Communications</i> , 2021, 12, 63.	5.8	303

#	ARTICLE	IF	CITATIONS
379	Human Monoclonal Antibodies: On the Menu of Targeted Therapeutics Against COVID-19. <i>Virologica Sinica</i> , 2020, 35, 713-724.	1.2	10
380	Correlates of protection against SARS-CoV-2 in rhesus macaques. <i>Nature</i> , 2021, 590, 630-634.	13.7	995
381	Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	283
382	The impact of structural bioinformatics tools and resources on SARS-CoV-2 research and therapeutic strategies. <i>Briefings in Bioinformatics</i> , 2021, 22, 742-768.	3.2	29
383	Role of Immunoglobulin M and A Antibodies in the Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2. <i>Journal of Infectious Diseases</i> , 2021, 223, 957-970.	1.9	64
384	Double lock of a potent human therapeutic monoclonal antibody against SARS-CoV-2. <i>National Science Review</i> , 2021, 8, nwaa297.	4.6	24
438	Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population. <i>Journal of Clinical Investigation</i> , 2020, 130, 6141-6150.	3.9	375
439	A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody. <i>PLoS Pathogens</i> , 2020, 16, e1009089.	2.1	55
440	Medicamentos e tratamentos para a Covid-19. <i>Estudos Avancados</i> , 2020, 34, 7-27.	0.2	15
442	Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. <i>ELife</i> , 2020, 9, .	2.8	1,239
443	Immunology of SARS-CoV-2 infections and vaccines. <i>Advances in Immunology</i> , 2021, 151, 49-97.	1.1	12
444	How Antibodies Recognize Pathogenic Viruses: Structural Correlates of Antibody Neutralization of HIV-1, SARS-CoV-2, and Zika. <i>Viruses</i> , 2021, 13, 2106.	1.5	7
445	Kinetics of Neutralizing Antibody Response Underscores Clinical COVID-19 Progression. <i>Journal of Immunology Research</i> , 2021, 2021, 1-11.	0.9	4
446	Rational preparation and application of a mRNA delivery system with cytidinyl/cationic lipid. <i>Journal of Controlled Release</i> , 2021, 340, 114-124.	4.8	11
448	A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administration. <i>Cell Reports</i> , 2021, 37, 109869.	2.9	59
449	InÂvivo characterization of emerging SARS-CoV-2 variant infectivity and human antibody escape potential. <i>Cell Reports</i> , 2021, 37, 109838.	2.9	8
450	Structure-guided antibody cocktail for prevention and treatment of COVID-19. <i>PLoS Pathogens</i> , 2021, 17, e1009704.	2.1	12
452	Key Substitutions in the Spike Protein of SARS-CoV-2 Variants Can Predict Resistance to Monoclonal Antibodies, but Other Substitutions Can Modify the Effects. <i>Journal of Virology</i> , 2022, 96, JVI0111021.	1.5	29

#	ARTICLE	IF	CITATIONS
453	Distant residues modulate conformational opening in SARS-CoV-2 spike protein. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	69
454	Characterization of SARS-CoV-2-specific humoral immunity and its potential applications and therapeutic prospects. Cellular and Molecular Immunology, 2022, 19, 150-157.	4.8	43
456	<scp>COVID</scp>â€19 vaccination in patients with heart failure: a position paper of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2021, 23, 1806-1818.	2.9	32
457	Current trends in diagnosis and treatment strategies of COVID-19 infection. Environmental Science and Pollution Research, 2021, 28, 64987-65013.	2.7	3
458	COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models. Nature Communications, 2021, 12, 6097.	5.8	38
460	Mechanisms of Lung Injury Induced by SARS-CoV-2 Infection. Physiology, 2022, 37, 88-100.	1.6	18
461	Monoclonal antibodies protect aged rhesus macaques from SARS-CoV-2-induced immune activation and neuroinflammation. Cell Reports, 2021, 37, 109942.	2.9	9
462	Isolation of a panel of ultra-potent human antibodies neutralizing SARS-CoV-2 and viral variants of concern. Cell Discovery, 2021, 7, 96.	3.1	21
463	Computational Design of Potent D-Peptide Inhibitors of SARS-CoV-2. Journal of Medicinal Chemistry, 2021, 64, 14955-14967.	2.9	28
465	Structural mechanism of SARS-CoV-2 neutralization by two murine antibodies targeting the RBD. Cell Reports, 2021, 37, 109881.	2.9	14
466	Serological anti-SARS-CoV-2 neutralizing antibodies association to live virus neutralizing test titers in COVID-19 paucisymptomatic/symptomatic patients and vaccinated subjects. International Immunopharmacology, 2021, 101, 108215.	1.7	20
468	The demographic and serological characteristics of COVID-19 convalescent plasma donors: Identification of basic criteria for optimal donor selection. Transfusion and Apheresis Science, 2022, 61, 103302.	0.5	5
469	Complete protection by a single-dose skin patchâ€ delivered SARS-CoV-2 spike vaccine. Science Advances, 2021, 7, eabj8065.	4.7	31
470	Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity. Cells, 2021, 10, 2949.	1.8	26
471	Neutralizing Antibodies to SARSâ€CoVâ€2 Selected from a Human Antibody Library Constructed Decades Ago. Advanced Science, 2022, 9, e2102181.	5.6	14
472	Antiviral Therapeutics: Key to Curbing the COVID-19 Pandemic. American Journal of Medicine, 2021, , .	0.6	0
473	Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations. Nature Immunology, 2021, 22, 1503-1514.	7.0	40
474	Contributions of single-particle cryoelectron microscopy toward fighting COVID-19. Trends in Biochemical Sciences, 2022, 47, 117-123.	3.7	6

#	ARTICLE	IF	CITATIONS
479	Probing Affinity, Avidity, Anticooperativity, and Competition in Antibody and Receptor Binding to the SARS-CoV-2 Spike by Single Particle Mass Analyses. <i>ACS Central Science</i> , 2021, 7, 1863-1873.	5.3	20
480	Cross-reactivity of antibodies from non-hospitalized COVID-19 positive individuals against the native, B.1.351, B.1.617.2, and P.1 SARS-CoV-2 spike proteins. <i>Scientific Reports</i> , 2021, 11, 21601.	1.6	20
481	Self and Nonself Short Constituent Sequences of Amino Acids in the SARS-CoV-2 Proteome for Vaccine Development. <i>Covid</i> , 2021, 1, 555-574.	0.7	4
482	A Novel Double Mosaic Virus-like Particle-Based Vaccine against SARS-CoV-2 Incorporates Both Receptor Binding Motif (RBM) and Fusion Domain. <i>Vaccines</i> , 2021, 9, 1287.	2.1	10
483	In Vivo Electroporation of Plasmid DNA: A Promising Strategy for Rapid, Inexpensive, and Flexible Delivery of Anti-Viral Monoclonal Antibodies. <i>Pharmaceutics</i> , 2021, 13, 1882.	2.0	6
484	Potent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants. <i>Nature Communications</i> , 2021, 12, 6304.	5.8	42
486	Editorial: The battle for survival between severe acute respiratory syndrome coronavirus 2 and human beings. <i>Current Opinion in HIV and AIDS</i> , 2020, 15, 325-327.	1.5	0
492	Generation and Effect Testing of a SARS-CoV-2 RBD-Targeted Polyclonal Therapeutic Antibody Based on a 2-D Airway Organoid Screening System. <i>Frontiers in Immunology</i> , 2021, 12, 689065.	2.2	6
493	Analysis of Glycosylation and Disulfide Bonding of Wild-Type SARS-CoV-2 Spike Glycoprotein. <i>Journal of Virology</i> , 2022, 96, JVI0162621.	1.5	24
494	Pathogenesis and Mechanism of Gastrointestinal Infection With COVID-19. <i>Frontiers in Immunology</i> , 2021, 12, 674074.	2.2	20
495	A Bacterial Cell-Based Assay To Study SARS-CoV-2 Protein-Protein Interactions. <i>MBio</i> , 2021, , e0293621.	1.8	1
497	Recombinant production of a functional SARS-CoV-2 spike receptor binding domain in the green algae <i>Chlamydomonas reinhardtii</i> . <i>PLoS ONE</i> , 2021, 16, e0257089.	1.1	20
498	Nanoparticulate CpG-adjuvanted SARS-CoV-2 S1 protein elicits broadly neutralizing and Th1-biased immunoreactivity in mice. <i>International Journal of Biological Macromolecules</i> , 2021, 193, 1885-1897.	3.6	12
499	Antibody cocktail effective against variants of SARS-CoV-2. <i>Journal of Biomedical Science</i> , 2021, 28, 80.	2.6	17
500	Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike. <i>MBio</i> , 2021, 12, e0297521.	1.8	24
501	Treatments for COVID-19: Lessons from 2020 and new therapeutic options. <i>Current Opinion in Pharmacology</i> , 2022, 62, 43-59.	1.7	23
502	Spherical Neutralizing Aptamer Inhibits SARS-CoV-2 Infection and Suppresses Mutational Escape. <i>Journal of the American Chemical Society</i> , 2021, 143, 21541-21548.	6.6	56
504	Is SARS-CoV-2 viral clearance in nasopharyngeal swabs an appropriate surrogate marker for clinical efficacy of neutralising antibody-based therapeutics?. <i>Reviews in Medical Virology</i> , 2022, 32, e2314.	3.9	7

#	ARTICLE	IF	CITATIONS
505	Pharmacological Agents for COVID-19 Patients. , 2021, , 151-166.		0
506	Structural basis and mode of action for two broadly neutralizing antibodies against SARS-CoV-2 emerging variants of concern. <i>Cell Reports</i> , 2022, 38, 110210.	2.9	96
507	A structural view of the SARS-CoV-2 virus and its assembly. <i>Current Opinion in Virology</i> , 2022, 52, 123-134.	2.6	42
509	Single-cell immunology of SARS-CoV-2 infection. <i>Nature Biotechnology</i> , 2022, 40, 30-41.	9.4	78
510	Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. <i>Nature</i> , 2022, 602, 671-675.	13.7	1,202
511	Thiol-based chemical probes exhibit antiviral activity against SARS-CoV-2 via allosteric disulfide disruption in the spike glycoprotein. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	28
512	The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans. <i>Science Translational Medicine</i> , 2022, 14, eab18124.	5.8	143
513	<i>In Vivo</i> Hematopoietic Stem Cell Gene Therapy for SARS-CoV2 Infection Using a Decoy Receptor. <i>Human Gene Therapy</i> , 2022, 33, 389-403.	1.4	5
514	Performance of a flow cytometry-based immunoassay for detection of antibodies binding to SARS-CoV-2 spike protein. <i>Scientific Reports</i> , 2022, 12, 586.	1.6	1
515	Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies. <i>Emerging Microbes and Infections</i> , 2022, 11, 477-481.	3.0	104
517	A possible dose-response equation: Viral load after plasma infusion in COVID-19 patients and anti-SARS-CoV-2 antibody titers in convalescent plasma. <i>Transfusion Medicine</i> , 2022, , e12852.	0.5	0
518	mRNA-1273 vaccine-induced antibodies maintain Fc effector functions across SARS-CoV-2 variants of concern. <i>Immunity</i> , 2022, 55, 355-365.e4.	6.6	76
519	Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines. <i>Pharmacological Reviews</i> , 2022, 74, 313-339.	7.1	9
520	The mutational dynamics of the SARS-CoV-2 virus in serial passages in vitro. <i>Virologica Sinica</i> , 2022, 37, 198-207.	1.2	12
521	Immunization with synthetic SARS-CoV-2 S glycoprotein virus-like particles protects macaques from infection. <i>Cell Reports Medicine</i> , 2022, 3, 100528.	3.3	6
522	A new testing platform using fingerstick blood for quantitative antibody response evaluation after SARS-CoV-2 vaccination. <i>Emerging Microbes and Infections</i> , 2022, 11, 250-259.	3.0	3
523	Preclinical evaluation of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B. <i>Science Advances</i> , 2022, 8, eabj9815.	4.7	29
524	Rapid identification of neutralizing antibodies against SARS-CoV-2 variants by mRNA display. <i>Cell Reports</i> , 2022, 38, 110348.	2.9	14

#	ARTICLE	IF	CITATIONS
525	Longitudinal immune profiling reveals dominant epitopes mediating long-term humoral immunity in COVID-19 convalescent individuals. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 1225-1241.	1.5	5
526	A pandemic-enabled comparison of discovery platforms demonstrates a naïve antibody library can match the best immune-sourced antibodies. <i>Nature Communications</i> , 2022, 13, 462.	5.8	17
528	Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection. <i>Journal of Biomedical Science</i> , 2022, 29, 1.	2.6	144
529	IgG Against Human Betacoronavirus Spike Proteins Correlates With SARS-CoV-2 Anti-Spike IgG Responses and COVID-19 Disease Severity. <i>Journal of Infectious Diseases</i> , 2022, 226, 474-484.	1.9	11
531	Evaluation of Drug Repositioning by Molecular Docking of Pharmaceutical Resources to Identification of Potential SARS-CoV-2 Viral Inhibitors. , 0, , .		0
532	Standardized two-step testing of antibody activity in COVID-19 convalescent plasma. <i>IScience</i> , 2022, 25, 103602.	1.9	6
533	An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. <i>Nature Medicine</i> , 2022, 28, 490-495.	15.2	577
534	Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals. <i>Cell</i> , 2022, 185, 1008-1024.e15.	13.5	101
535	Efficacy and Safety of Regdanvimab (CT-P59): A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial in Outpatients With Mild-to-Moderate Coronavirus Disease 2019. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac053.	0.4	38
536	CoV501, a self-adjuvanting peptide vaccine conjugated with TLR7 agonists, against SARS-CoV-2 induces protective immunity. <i>Cell Discovery</i> , 2022, 8, 9.	3.1	12
537	Regdanvimab in patients with mild-to-moderate SARS-CoV-2 infection: A propensity score-matched retrospective cohort study. <i>International Immunopharmacology</i> , 2022, 106, 108570.	1.7	13
538	Monoclonal antibodies targeting two immunodominant epitopes on the Spike protein neutralize emerging SARS-CoV-2 variants of concern. <i>EBioMedicine</i> , 2022, 76, 103818.	2.7	14
539	Human Antibodies for Viral Infections. <i>Annual Review of Immunology</i> , 2022, 40, 349-386.	9.5	23
540	Designed SARS-CoV-2 receptor binding domain variants form stable monomers. <i>Biotechnology Journal</i> , 2022, 17, e2100422.	1.8	8
541	A combination of two human neutralizing antibodies prevents SARS-CoV-2 infection in cynomolgus macaques. <i>Med</i> , 2022, 3, 188-203.e4.	2.2	11
543	Neutralizing monoclonal antibodies against highly pathogenic coronaviruses. <i>Current Opinion in Virology</i> , 2022, 53, 101199.	2.6	2
544	Monoclonal Antibody Therapeutics for Infectious Diseases: Beyond Normal Human Immunoglobulin. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
545	A high-throughput single cell-based antibody discovery approach against the full-length SARS-CoV-2 spike protein suggests a lack of neutralizing antibodies targeting the highly conserved S2 domain. <i>Briefings in Bioinformatics</i> , 2022, 23, .	3.2	2

#	ARTICLE	IF	CITATIONS
546	Development of SARS-CoV2 humoral response including neutralizing antibodies is not sufficient to protect patients against fatal infection. <i>Scientific Reports</i> , 2022, 12, 2077.	1.6	8
548	A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection. <i>Science Translational Medicine</i> , 2022, 14, eabi9215.	5.8	123
549	An adjuvant strategy enabled by modulation of the physical properties of microbial ligands expands antigen immunogenicity. <i>Cell</i> , 2022, 185, 614-629.e21.	13.5	40
550	Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. <i>Lancet, The</i> , 2022, 399, 665-676.	6.3	280
553	SARS-CoV-2 Omicron-neutralizing memory B cells are elicited by two doses of BNT162b2 mRNA vaccine. <i>Science Immunology</i> , 2022, 7, eabn8590.	5.6	88
554	Elicitation of potent SARS-CoV-2 neutralizing antibody responses through immunization with a versatile adenovirus-inspired multimerization platform. <i>Molecular Therapy</i> , 2022, 30, 1913-1925.	3.7	21
555	A SARS-CoV-2 variant elicits an antibody response with a shifted immunodominance hierarchy. <i>PLoS Pathogens</i> , 2022, 18, e1010248.	2.1	48
556	Parallel profiling of antigenicity alteration and immune escape of SARS-CoV-2 Omicron and other variants. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 42.	7.1	25
558	A Potent and Protective Human Neutralizing Antibody Against SARS-CoV-2 Variants. <i>Frontiers in Immunology</i> , 2021, 12, 766821.	2.2	15
559	SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity. <i>Cell Reports</i> , 2021, 37, 110143.	2.9	94
560	Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. <i>Nature</i> , 0, , .	13.7	90
561	Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. <i>Nature</i> , 0, , .	13.7	101
562	Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. <i>Nature</i> , 0, , .	13.7	72
563	Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. <i>Nature</i> , 0, , .	13.7	88
564	Conformational dynamics of the Beta and Kappa SARS-CoV-2 spike proteins and their complexes with ACE2 receptor revealed by cryo-EM. <i>Nature Communications</i> , 2021, 12, 7345.	5.8	58
565	Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. <i>Nature</i> , 2022, 602, 657-663.	13.7	1,350
566	Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. <i>Nature</i> , 2022, 602, 664-670.	13.7	917
567	Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. <i>Nature</i> , 2022, 602, 676-681.	13.7	1,038

#	ARTICLE	IF	CITATIONS
568	Deep dissection of the antiviral immune profile of patients with COVID-19. <i>Communications Biology</i> , 2021, 4, 1389.	2.0	9
569	SARS-CoV-2 spreads through cell-to-cell transmission. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	145
570	Rapid discovery of diverse neutralizing SARS-CoV-2 antibodies from large-scale synthetic phage libraries. <i>MAbs</i> , 2022, 14, 2002236.	2.6	14
580	Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants. <i>Science</i> , 2021, 374, 1621-1626.	6.0	232
581	Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement. <i>Science</i> , 2022, 375, 864-868.	6.0	394
583	Highly synergistic combinations of nanobodies that target SARS-CoV-2 and are resistant to escape. <i>ELife</i> , 2021, 10, .	2.8	36
584	Practical Considerations for the Scale-Up of Chinese Hamster Ovary (CHO) Cell Cultures. <i>Cell Engineering</i> , 2021, , 367-400.	0.4	1
585	Anti-SARS CoV-2 IgG in COVID-19 Patients with Hematological Diseases: A Single-center, Retrospective Study in Japan. <i>Internal Medicine</i> , 2022, 61, 1681-1686.	0.3	2
586	SARS-CoV-2 and Coronavirus Disease Mitigation: Treatment Options, Vaccinations and Variants. <i>Pathogens</i> , 2022, 11, 275.	1.2	9
587	Bispecific antiviral neutralizing antibodies are twice as nice. <i>Nature Immunology</i> , 2022, 23, 346-347.	7.0	3
588	Comparative Magnitude and Persistence of Humoral SARS-CoV-2 Vaccination Responses in the Adult Population in Germany. <i>Frontiers in Immunology</i> , 2022, 13, 828053.	2.2	11
589	Identification of a Novel Neutralizing Epitope on the N-Terminal Domain of the Human Coronavirus 229E Spike Protein. <i>Journal of Virology</i> , 2022, 96, JVI0195521.	1.5	2
590	Therapeutic antibodies for COVID-19: is a new age of IgM, IgA and bispecific antibodies coming?. <i>MAbs</i> , 2022, 14, 2031483.	2.6	15
591	Performance evaluation of an automatic chemiluminescence immune platform for SARS-CoV-2 neutralizing antibody after vaccination in real world. <i>BMC Infectious Diseases</i> , 2022, 22, 157.	1.3	2
592	An engineered bispecific human monoclonal antibody against SARS-CoV-2. <i>Nature Immunology</i> , 2022, 23, 423-430.	7.0	38
593	Structural basis for SARS-CoV-2 Delta variant recognition of ACE2 receptor and broadly neutralizing antibodies. <i>Nature Communications</i> , 2022, 13, 871.	5.8	107
594	Characterization of the antibody response to SARS-CoV-2 in a mildly affected pediatric population. <i>Pediatric Allergy and Immunology</i> , 2022, 33, e13737.	1.1	5
595	Modeling how antibody responses may determine the efficacy of COVID-19 vaccines. <i>Nature Computational Science</i> , 2022, 2, 123-131.	3.8	39

#	ARTICLE	IF	CITATIONS
596	Multivariate mining of an alpaca immune repertoire identifies potent cross-neutralizing SARS-CoV-2 nanobodies. <i>Science Advances</i> , 2022, 8, eabm0220.	4.7	18
597	Nonself Mutations in the Spike Protein Suggest an Increase in the Antigenicity and a Decrease in the Virulence of the Omicron Variant of SARS-CoV-2. <i>Covid</i> , 2022, 2, 407-418.	0.7	3
598	Antibody evasion properties of SARS-CoV-2 Omicron sublineages. <i>Nature</i> , 2022, 604, 553-556.	13.7	649
599	Short-Term Instantaneous Prophylaxis and Efficient Treatment Against SARS-CoV-2 in hACE2 Mice Conferred by an Intranasal Nanobody (Nb22). <i>Frontiers in Immunology</i> , 2022, 13, 865401.	2.2	8
603	The role of neutralizing antibodies by sVNT after two doses of BNT162b2 mRNA vaccine in a cohort of Italian healthcare workers. <i>Clinical Chemistry and Laboratory Medicine</i> , 2022, 60, 934-940.	1.4	5
604	An antibody-escape estimator for mutations to the SARS-CoV-2 receptor-binding domain. <i>Virus Evolution</i> , 2022, 8, veac021.	2.2	93
606	Pre-existing SARS-CoV-2 immunity influences potency, breadth, and durability of the humoral response to SARS-CoV-2 vaccination. <i>Cell Reports Medicine</i> , 2022, 3, 100603.	3.3	27
607	Monospecific and bispecific monoclonal SARS-CoV-2 neutralizing antibodies that maintain potency against B.1.617. <i>Nature Communications</i> , 2022, 13, 1638.	5.8	11
609	Efficient discovery of SARS-CoV-2-neutralizing antibodies via B cell receptor sequencing and ligand blocking. <i>Nature Biotechnology</i> , 2022, 40, 1270-1275.	9.4	27
610	Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529. <i>Science</i> , 2022, 376, eabn8897.	6.0	119
612	Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies. <i>Nature Medicine</i> , 2022, 28, 1297-1302.	15.2	235
613	Neutralizing Monoclonal Antibodies Inhibit SARS-CoV-2 Infection through Blocking Membrane Fusion. <i>Microbiology Spectrum</i> , 2022, 10, e0181421.	1.2	9
614	The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studies. <i>EBioMedicine</i> , 2022, 77, 103902.	2.7	23
618	Decreased and Heterogeneous Neutralizing Antibody Responses Against RBD of SARS-CoV-2 Variants After mRNA Vaccination. <i>Frontiers in Immunology</i> , 2022, 13, 816389.	2.2	5
619	SARS-CoV-2 BA.1 variant is neutralized by vaccine booster-elicited serum but evades most convalescent serum and therapeutic antibodies. <i>Science Translational Medicine</i> , 2022, 14, eabn8543.	5.8	75
621	RBD trimer mRNA vaccine elicits broad and protective immune responses against SARS-CoV-2 variants. <i>IScience</i> , 2022, 25, 104043.	1.9	19
622	Upstream cell culture process characterization and in-process control strategy development at pandemic speed. <i>MAbs</i> , 2022, 14, 2060724.	2.6	9
623	Neutralization or enhancement of SARS-CoV-2 infection by a monoclonal antibody targeting a specific epitope in the spike receptor-binding domain. <i>Antiviral Research</i> , 2022, 200, 105290.	1.9	3

#	ARTICLE	IF	CITATIONS
624	Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-CoV-2 spike proteins. <i>Immunity</i> , 2022, 55, 998-1012.e8.	6.6	86
626	Systematic profiling of antigen bias in humoral response against SARS-CoV-2. <i>Virus Research</i> , 2022, 312, 198711.	1.1	0
627	Isolation of human monoclonal antibodies with neutralizing activity to a broad spectrum of SARS-CoV-2 viruses including the Omicron variants. <i>Antiviral Research</i> , 2022, 201, 105297.	1.9	3
628	Application of the SARS-CoV-2-S1 ACE-2 receptor interaction as the basis of the fully automated assay to detect neutralizing SARS-CoV-2-S1 antibodies in blood samples. <i>Journal of Immunological Methods</i> , 2022, 504, 113258.	0.6	2
629	A comprehensive evolutionary and epidemiological characterization of insertion and deletion mutations in SARS-CoV-2 genomes. <i>Virus Evolution</i> , 2021, 7, veab104.	2.2	9
630	Computational Insights Into the Effects of the R190K and N121Q Mutations on the SARS-CoV-2 Spike Complex With Biliverdin. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 791885.	1.6	4
631	Nonmuscle myosin heavy chain IIA facilitates SARS-CoV-2 infection in human pulmonary cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	25
632	Human neutralizing antibodies for SARS-CoV-2 prevention and immunotherapy. <i>Immunotherapy Advances</i> , 2022, 2, .	1.2	9
635	Neutralizing antibody responses over time in demographically and clinically diverse individuals recovered from SARS-CoV-2 infection in the United States and Peru: A cohort study. <i>PLoS Medicine</i> , 2021, 18, e1003868.	3.9	20
636	Monoclonal Antibodies against SARS-CoV-2: Current Scenario and Future Perspectives. <i>Pharmaceuticals</i> , 2021, 14, 1272.	1.7	20
637	Quality comparability assessment of a SARS-CoV-2-neutralizing antibody across transient, mini-pool-derived and single-clone CHO cells. <i>MAbs</i> , 2022, 14, 2005507.	2.6	8
639	Evaluation of a Lateral Flow Immunoassay COVIDTECH [®] ; SARS-CoV-2 IgM/IgG Antibody Rapid Test. <i>Japanese Journal of Infectious Diseases</i> , 2022, 75, 334-340.	0.5	3
641	Phosphate-mediated coanchoring of RBD immunogens and molecular adjuvants to alum potentiates humoral immunity against SARS-CoV-2. <i>Science Advances</i> , 2021, 7, eabj6538.	4.7	19
643	Recent Developments in SARS-CoV-2 Neutralizing Antibody Detection Methods. <i>Current Medical Science</i> , 2021, 41, 1052-1064.	0.7	16
644	Foxp3+ CD4+ regulatory T cells control dendritic cells in inducing antigen-specific immunity to emerging SARS-CoV-2 antigens. <i>PLoS Pathogens</i> , 2021, 17, e1010085.	2.1	13
645	Multiple Routes of Antibody-Dependent Enhancement of SARS-CoV-2 Infection. <i>Microbiology Spectrum</i> , 2022, 10, e0155321.	1.2	30
646	Human-Immune-System (HIS) humanized mouse model (DRAGA: HLA-A2.HLA-DR4.Rag1KO.II-2R1 ³ cKO.NOD) for COVID-19. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-16.	1.4	6
647	Structures of Omicron spike complexes and implications for neutralizing antibody development. <i>Cell Reports</i> , 2022, 39, 110770.	2.9	47

#	ARTICLE	IF	CITATIONS
648	The kinetics and predictors of anti-SARS-CoV-2 antibodies up to eight months after symptomatic COVID-19: a Czech cross-sectional study. <i>Journal of Medical Virology</i> , 2022, , .	2.5	7
649	BNT162b2, mRNA-1273, and Sputnik V Vaccines Induce Comparable Immune Responses on a Par With Severe Course of COVID-19. <i>Frontiers in Immunology</i> , 2022, 13, 797918.	2.2	1
650	Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern: A Perspective for Emerging More Transmissible and Vaccine-Resistant Strains. <i>Viruses</i> , 2022, 14, 827.	1.5	14
651	Prolonged Protective Immunity Induced by Mild SARS-CoV-2 Infection of K18-hACE2 Mice. <i>Vaccines</i> , 2022, 10, 613.	2.1	2
652	SARS-CoV-2 Spike Protein Expression In Vitro and Hematologic Effects in Mice Vaccinated With AZD1222 (ChAdOx1 nCoV-19). <i>Frontiers in Immunology</i> , 2022, 13, 836492.	2.2	8
653	Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19. <i>New England Journal of Medicine</i> , 2022, 386, 2188-2200.	13.9	450
655	SARS-CoV-2 pan-variant inhibitory peptides deter S1-ACE2 interaction and neutralize delta and omicron pseudoviruses. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 2042-2056.	1.9	8
656	Broadly neutralizing antibodies against SARS-CoV-2 variants. , 2022, 1, 20220005.		3
657	Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants. <i>BioDrugs</i> , 2022, 36, 231-323.	2.2	24
658	An antibody targeting the N-terminal domain of SARS-CoV-2 disrupts the spike trimer. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	14
659	SARS-CoV-2 Omicron variant: recent progress and future perspectives. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 141.	7.1	315
660	A combination of potently neutralizing monoclonal antibodies isolated from an Indian convalescent donor protects against the SARS-CoV-2 Delta variant. <i>PLoS Pathogens</i> , 2022, 18, e1010465.	2.1	8
662	Novel super-neutralizing antibody UT28K is capable of protecting against infection from a wide variety of SARS-CoV-2 variants. <i>MAbs</i> , 2022, 14, 2072455.	2.6	9
663	Structural mapping of antibody landscapes to human betacoronavirus spike proteins. <i>Science Advances</i> , 2022, 8, eabn2911.	4.7	28
664	Off-the-shelf CAR natural killer cells secreting IL-15 target spike in treating COVID-19. <i>Nature Communications</i> , 2022, 13, 2576.	5.8	21
665	Structural insights of a highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibody. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2120976119.	3.3	27
666	Antibody evasion of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2, and BA.3 sub-lineages. <i>Cell Host and Microbe</i> , 2022, 30, 1077-1083.e4.	5.1	132
667	Analysis of a SARS-CoV-2 convalescent cohort identified a common strategy for escape of vaccine-induced anti-RBD antibodies by Beta and Omicron variants. <i>EBioMedicine</i> , 2022, 80, 104025.	2.7	13

#	ARTICLE	IF	CITATIONS
668	Antibody-mediated neutralization of SARS-CoV-2. <i>Immunity</i> , 2022, 55, 925-944.	6.6	74
669	Complex Mutation Pattern of Omicron BA.2: Evading Antibodies without Losing Receptor Interactions. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5534.	1.8	10
670	Point mutations in SARS-CoV-2 variants induce long-range dynamical perturbations in neutralizing antibodies. <i>Chemical Science</i> , 2022, 13, 7224-7239.	3.7	6
671	Epitope Mapping and Binding Assessment by Solid-State NMR Provide a Way for the Development of Biologics under the Quality by Design Paradigm. <i>Journal of the American Chemical Society</i> , 2022, 144, 10006-10016.	6.6	9
672	Phage-like particle vaccines are highly immunogenic and protect against pathogenic coronavirus infection and disease. <i>Npj Vaccines</i> , 2022, 7, .	2.9	8
673	Development of an LNP-Encapsulated mRNA-RBD Vaccine against SARS-CoV-2 and Its Variants. <i>Pharmaceutics</i> , 2022, 14, 1101.	2.0	15
674	It is Never Too Late for a Cocktail - Development and Analytical Characterization of Fixed-dose Antibody Combinations. <i>Journal of Pharmaceutical Sciences</i> , 2022, 111, 2149-2157.	1.6	2
675	Animal models for studying coronavirus infections and developing antiviral agents and vaccines. <i>Antiviral Research</i> , 2022, 203, 105345.	1.9	7
676	Protective neutralizing epitopes in SARS-CoV-2. <i>Immunological Reviews</i> , 2022, 310, 76-92.	2.8	23
679	Evaluation of strategies to modify Anti-SARS-CoV-2 monoclonal antibodies for optimal functionality as therapeutics. <i>PLoS ONE</i> , 2022, 17, e0267796.	1.1	3
680	COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis. <i>Clinical and Molecular Hepatology</i> , 2022, 28, 890-911.	4.5	29
682	Correlates of protection against SARS-CoV-2 infection and COVID-19 disease. <i>Immunological Reviews</i> , 2022, 310, 6-26.	2.8	138
683	SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19. <i>The Cochrane Library</i> , 2022, 2022, .	1.5	20
684	Monoclonal Antibodies with Extended Half-Life to Prevent Covid-19. <i>New England Journal of Medicine</i> , 2022, 386, 2236-2238.	13.9	3
685	SARS-CoV-2 Omicron Variants Reduce Antibody Neutralization and Acquire Usage of Mouse ACE2. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	10
686	The Cellular Characterization of SARS-CoV-2 Spike Protein in Virus-Infected Cells Using the Receptor Binding Domain Binding Specific Human Monoclonal Antibodies. <i>Journal of Virology</i> , 0, , .	1.5	0
688	Role of anticoagulation in lowering the mortality in hospitalized covid-19 patients. <i>Journal of King Abdulaziz University, Islamic Economics</i> , 2022, 43, 541-550.	0.5	0
689	Development of an efficient reproducible cell-cell transmission assay for rapid quantification of SARS-CoV-2 Spike interaction with hACE2. <i>Cell Reports Methods</i> , 2022, , 100252.	1.4	1

#	ARTICLE	IF	CITATIONS
690	Monoclonal antibody therapeutics for infectious diseases: Beyond normal human immunoglobulin. , 2022, 240, 108233.		9
691	BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature, 2022, 608, 593-602.	13.7	889
692	Antibodies to combat viral infections: development strategies and progress. Nature Reviews Drug Discovery, 2022, 21, 676-696.	21.5	68
693	Structural and functional analysis of a potent human neutralizing antibody against enterovirus A71. Science China Life Sciences, 0, , .	2.3	0
694	Potent human broadly SARS-CoV-2 neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2. Journal of Experimental Medicine, 2022, 219, .	4.2	34
695	Tixagevimab + Cilgavimab: First Approval. Drugs, 2022, 82, 1001-1010.	4.9	31
696	Broad Cross-Reactive IgA and IgG against Human Coronaviruses in Milk Induced by COVID-19 Vaccination and Infection. Vaccines, 2022, 10, 980.	2.1	9
697	Single-cell profiling of the antigen-specific response to BNT162b2 SARS-CoV-2 RNA vaccine. Nature Communications, 2022, 13, .	5.8	28
698	Therapeutic efficacy of monoclonal antibodies and antivirals against SARS-CoV-2 Omicron BA.1 in Syrian hamsters. Nature Microbiology, 2022, 7, 1252-1258.	5.9	20
699	A one-year follow-up study on dynamic changes of leukocyte subsets and virus-specific antibodies of patients with COVID-19 in Sichuan, China. International Journal of Medical Sciences, 2022, 19, 1122-1130.	1.1	0
700	Review on In silico Methods, High-throughput Screening Techniques, and Cell Culture Based In Vitro Assays for SARS-CoV-2... Current Medicinal Chemistry, 2022, 29, .	1.2	3
702	The humoral response and antibodies against SARS-CoV-2 infection. Nature Immunology, 2022, 23, 1008-1020.	7.0	84
703	A bivalent SARS-CoV-2 monoclonal antibody combination does not affect the immunogenicity of a vector-based COVID-19 vaccine in macaques. Science Translational Medicine, 2022, 14, .	5.8	3
704	Landscape of B Cell Receptor Repertoires in COVID-19 Patients Revealed Through CDR3 Sequencing of Immunoglobulin Heavy and Light Chains. Immunological Investigations, 2022, 51, 1994-2008.	1.0	3
705	SARS-CoV-2 Omicron sublineages exhibit distinct antibody escape patterns. Cell Host and Microbe, 2022, 30, 1231-1241.e6.	5.1	55
706	Suppression of SARS-CoV-2 Replication with Stabilized and Click Chemistry Modified siRNAs. Angewandte Chemie - International Edition, 2022, 61, .	7.2	6
707	COVID-19 and plasma cells: Is there long-lived protection?*. Immunological Reviews, 2022, 309, 40-63.	2.8	26
708	Guardians of the oral and nasopharyngeal galaxy: IgA and protection against SARS-CoV-2 infection*. Immunological Reviews, 2022, 309, 75-85.	2.8	32

#	ARTICLE	IF	CITATIONS
709	Suppression of SARS-CoV-2 Replication with Stabilized and Click-Chemistry Modified siRNAs. <i>Angewandte Chemie</i> , 0, .	1.6	0
710	Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models. <i>Science</i> , 2022, 377, .	6.0	120
711	Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains. <i>Nature Communications</i> , 2022, 13, .	5.8	93
712	Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5. <i>Nature</i> , 2022, 608, 603-608.	13.7	541
713	Avidity in antibody effector functions and biotherapeutic drug design. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 715-735.	21.5	65
716	A mRNA Vaccine Encoding for a RBD 60-mer Nanoparticle Elicits Neutralizing Antibodies and Protective Immunity Against the SARS-CoV-2 Delta Variant in Transgenic K18-hACE2 Mice. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
717	Structure-selected RBM immunogens prime polyclonal memory responses that neutralize SARS-CoV-2 variants of concern. <i>PLoS Pathogens</i> , 2022, 18, e1010686.	2.1	2
718	Immune Evasion by the Highly Mutated SARS-CoV-2 Omicron Variant. <i>Infection and Drug Resistance</i> , 0, Volume 15, 4013-4027.	1.1	4
719	MicroRNAs as Potential Tools for Predicting Cancer Patients' Susceptibility to SARS-CoV-2 Infection and Vaccination Response. <i>Cells</i> , 2022, 11, 2279.	1.8	6
723	SARS-CoV-2 antibody progression and neutralizing potential in mild symptomatic COVID-19 patients – a comparative long term post-infection study. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
726	A public antibody class recognizes an S2 epitope exposed on open conformations of SARS-CoV-2 spike. <i>Nature Communications</i> , 2022, 13, .	5.8	34
730	Ultrabright nanoparticle-labeled lateral flow immunoassay for detection of anti-SARS-CoV-2 neutralizing antibodies in human serum. <i>Biomaterials</i> , 2022, 288, 121694.	5.7	15
731	Two Years into the COVID-19 Pandemic: Lessons Learned. <i>ACS Infectious Diseases</i> , 2022, 8, 1758-1814.	1.8	47
732	The spike receptor-binding motif G496S substitution determines the replication fitness of SARS-CoV-2 Omicron sublineage. <i>Emerging Microbes and Infections</i> , 2022, 11, 2093-2101.	3.0	5
733	Qualification of a Bi-layer Interferometry Assay to Support AZD7442 Resistance Monitoring. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	2
735	Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	15
736	Monoclonal antibodies: a remedial approach to prevent SARS-CoV-2 infection. <i>3 Biotech</i> , 2022, 12, .	1.1	4
737	Structural basis of a two-antibody cocktail exhibiting highly potent and broadly neutralizing activities against SARS-CoV-2 variants including diverse Omicron sublineages. <i>Cell Discovery</i> , 2022, 8, .	3.1	13

#	ARTICLE	IF	CITATIONS
738	Converting non-neutralizing SARS-CoV-2 antibodies into broad-spectrum inhibitors. <i>Nature Chemical Biology</i> , 2022, 18, 1270-1276.	3.9	8
739	Single domain antibodies derived from ancient animals as broadly neutralizing agents for SARS-CoV-2 and other coronaviruses. <i>Biomedical Engineering Advances</i> , 2022, 4, 100054.	2.2	3
740	Antibody-mediated immunity to SARS-CoV-2 spike. <i>Advances in Immunology</i> , 2022, , 1-69.	1.1	12
741	Evolution of Anti-SARS-CoV-2 Therapeutic Antibodies. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9763.	1.8	17
742	Engineered DNA-encoded monoclonal antibodies targeting <i>Plasmodium falciparum</i> circumsporozoite protein confer single dose protection in a murine malaria challenge model. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
743	Design of immunogens for eliciting antibody responses that may protect against SARS-CoV-2 variants. <i>PLoS Computational Biology</i> , 2022, 18, e1010563.	1.5	4
744	Potential of conserved antigenic sites in development of universal SARS-like coronavirus vaccines. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
746	Structure-based neutralizing mechanisms for SARS-CoV-2 antibodies. <i>Emerging Microbes and Infections</i> , 2022, 11, 2412-2422.	3.0	10
748	A counterintuitive antibody cocktail disrupts coxsackievirus. <i>Cell Host and Microbe</i> , 2022, 30, 1194-1195.	5.1	1
749	Prospects of animal models and their application in studies on adaptive immunity to SARS-CoV-2. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
750	An antibody cocktail with broadened mutational resistance and effective protection against SARS-CoV-2. <i>Science China Life Sciences</i> , 0, , .	2.3	2
752	Engineering recombinantly expressed lectin-based antiviral agents. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	2
753	Preventing SARS-CoV-2 Infection Using Anti-spike Nanobody-IFN- γ Conjugated Exosomes. <i>Pharmaceutical Research</i> , 0, , .	1.7	2
754	Potent monoclonal antibodies neutralize Omicron sublineages and other SARS-CoV-2 variants. <i>Cell Reports</i> , 2022, 41, 111528.	2.9	6
755	Therapeutic Role of Neutralizing Antibody for the Treatment against SARS-CoV-2 and Its Emerging Variants: A Clinical and Pre-Clinical Perspective. <i>Vaccines</i> , 2022, 10, 1612.	2.1	14
756	Antigenic characterization of the SARS-CoV-2 Omicron subvariant BA.2.75. <i>Cell Host and Microbe</i> , 2022, 30, 1512-1517.e4.	5.1	73
757	Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses. <i>Nature Reviews Immunology</i> , 2023, 23, 189-199.	10.6	112
758	Anti-SARS-CoV-2 immunoadhesin remains effective against Omicron and other emerging variants of concern. <i>IScience</i> , 2022, 25, 105193.	1.9	7

#	ARTICLE	IF	CITATIONS
759	A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies. <i>Journal of Biomedical Science</i> , 2022, 29, .	2.6	64
760	Differential patterns of cross-reactive antibody response against SARS-CoV-2 spike protein detected for chronically ill and healthy COVID-19 naïve individuals. <i>Scientific Reports</i> , 2022, 12, .	1.6	8
761	Combating the SARS-CoV-2 Omicron (BA.1) and BA.2 with potent bispecific antibodies engineered from non-Omicron neutralizing antibodies. <i>Cell Discovery</i> , 2022, 8, .	3.1	10
762	A single intranasal administration of AdCOVID protects against SARS-CoV-2 infection in the upper and lower respiratory tracts. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	1.4	9
763	Characterization of the enhanced infectivity and antibody evasion of Omicron BA.2.75. <i>Cell Host and Microbe</i> , 2022, 30, 1527-1539.e5.	5.1	109
764	DNA-delivered antibody cocktail exhibits improved pharmacokinetics and confers prophylactic protection against SARS-CoV-2. <i>Nature Communications</i> , 2022, 13, .	5.8	15
767	Nebulized mRNA-Encoded Antibodies Protect Hamsters from SARS-CoV-2 Infection. <i>Advanced Science</i> , 2022, 9, .	5.6	12
768	Impairment of antiviral immune response and disruption of cellular functions by SARS-CoV-2 ORF7a and ORF7b. <i>IScience</i> , 2022, 25, 105444.	1.9	14
769	Efficacy of COVID-HiGIV in animal models of SARS-CoV-2 infection. <i>Scientific Reports</i> , 2022, 12, .	1.6	4
770	Tixagevimab/cilgavimab for prevention and treatment of COVID-19: a review. <i>Expert Review of Anti-Infective Therapy</i> , 0, , 1-11.	2.0	3
771	Neutralizing antibodies from the rare convalescent donors elicited antibody-dependent enhancement of SARS-CoV-2 variants infection. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	5
772	What Is New in Prophylaxis and Treatment of COVID-19 in Renal Transplant Patients? A Report from an ESOT Meeting on the Topic. <i>Transplantology</i> , 2022, 3, 288-306.	0.3	0
773	Intranasal SARS-CoV-2 spike-based immunisation adjuvanted with polyethyleneimine elicits mucosal and systemic humoral responses in mice. <i>Journal of Immunological Methods</i> , 2022, 511, 113380.	0.6	0
774	Assessment of the post-SARS-CoV-2 vaccination response depending on the epidemiological status, demographic parameters and levels of selected cytokines in medical personnel. <i>Postepy Dermatologii i Alergologii</i> , 2022, 39, 913-922.	0.4	0
775	SARS-CoV-2 spike conformation determines plasma neutralizing activity elicited by a wide panel of human vaccines. <i>Science Immunology</i> , 2022, 7, .	5.6	42
776	Structural Modeling of Adaptive Immune Responses to Infection. <i>Methods in Molecular Biology</i> , 2023, , 283-294.	0.4	0
777	Tfh cells and the germinal center are required for memory B cell formation & humoral immunity after ChAdOx1 nCoV-19 vaccination. <i>Cell Reports Medicine</i> , 2022, 3, 100845.	3.3	6
778	Serological fingerprints link antiviral activity of therapeutic antibodies to affinity and concentration. <i>Scientific Reports</i> , 2022, 12, .	1.6	2

#	ARTICLE	IF	CITATIONS
779	A novel plant-made monoclonal antibody enhances the synergetic potency of an antibody cocktail against the SARS-CoV-2 Omicron variant. <i>Plant Biotechnology Journal</i> , 2023, 21, 549-559.	4.1	8
780	ACE2: A Dilemma in Regulating SARS-CoV-2 Infection and its Metabolic Complications. <i>BIO Integration</i> , 2023, 4, .	0.9	0
781	CD4 and IL-2 mediated NK cell responses after COVID-19 infection and mRNA vaccination in adults. <i>Immunobiology</i> , 2023, 228, 152304.	0.8	2
782	Immunosenescence and inflamm-ageing in COVID-19. <i>Ageing Research Reviews</i> , 2023, 84, 101818.	5.0	18
785	Species-agnostic polymeric formulations for inhalable messenger RNA delivery to the lung. <i>Nature Materials</i> , 2023, 22, 369-379.	13.3	41
786	Weakened humoral and cellular immune response to the inactivated COVID-19 vaccines in Chinese individuals with obesity/overweight. <i>Genes and Diseases</i> , 2023, 10, 608-617.	1.5	5
787	Simultaneous detection of antibody responses to multiple SARS-CoV-2 antigens by a Western blot serological assay. <i>Applied Microbiology and Biotechnology</i> , 2022, 106, 8183-8194.	1.7	0
788	AZD7442 (Tixagevimab/Cilgavimab) for Post-Exposure Prophylaxis of Symptomatic Coronavirus Disease 2019. <i>Clinical Infectious Diseases</i> , 2023, 76, 1247-1256.	2.9	16
789	Broad strategies for neutralizing SARS-CoV-2 and other human coronaviruses with monoclonal antibodies. <i>Science China Life Sciences</i> , 2023, 66, 658-678.	2.3	3
791	Integrative transcriptome analysis of SARS-CoV-2 human-infected cells combined with deep learning algorithms identifies two potential cellular targets for the treatment of coronavirus disease. <i>Brazilian Journal of Microbiology</i> , 0, , .	0.8	1
792	Comparative analysis of SARS-CoV-2 Omicron BA.2.12.1 and BA.5.2 variants. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	11
793	Challenges and developments in universal vaccine design against SARS-CoV-2 variants. <i>Npj Vaccines</i> , 2022, 7, .	2.9	25
795	Characterization of Systemic and Mucosal Humoral Immune Responses to an Adjuvanted Intranasal SARS-CoV-2 Protein Subunit Vaccine Candidate in Mice. <i>Vaccines</i> , 2023, 11, 30.	2.1	3
797	Efficacy and Safety of Tixagevimab/Cilgavimab to Prevent COVID-19 (Pre-Exposure Prophylaxis): A Systematic Review and Meta-Analysis. <i>Diseases (Basel, Switzerland)</i> , 2022, 10, 118.	1.0	11
798	Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. <i>Cell</i> , 2023, 186, 279-286.e8.	13.5	455
799	Rational identification of potent and broad sarbecovirus-neutralizing antibody cocktails from SARS convalescents. <i>Cell Reports</i> , 2022, 41, 111845.	2.9	46
800	Neutralizing and enhancing antibodies against SARS-CoV-2. <i>Inflammation and Regeneration</i> , 2022, 42, .	1.5	6
801	Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution. <i>Nature</i> , 0, , .	13.7	187

#	ARTICLE	IF	CITATIONS
802	Safety of mRNA COVID-19 vaccinations in patients with allergic diseases. <i>Public Health in Practice</i> , 2023, 5, 100354.	0.7	0
803	mRNA-Based Vaccines and Therapeutics for COVID-19 and Future Pandemics. <i>Vaccines</i> , 2022, 10, 2150.	2.1	25
804	A molecular understanding of alphavirus entry and antibody protection. <i>Nature Reviews Microbiology</i> , 2023, 21, 396-407.	13.6	9
805	Antibody feedback contributes to facilitating the development of Omicron-reactive memory B cells in SARS-CoV-2 mRNA vaccinees. <i>Journal of Experimental Medicine</i> , 2023, 220, .	4.2	11
807	Approaches to expand the conventional toolbox for discovery and selection of antibodies with drug-like physicochemical properties. <i>MAbs</i> , 2023, 15, .	2.6	11
808	Use of Antiviral Agents and other Therapies for COVID-19. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2023, 44, 118-129.	0.8	3
809	Insight into free energy and dynamic cross-correlations of residue for binding affinity of antibody and receptor binding domain SARS-CoV-2. <i>Heliyon</i> , 2023, 9, e12667.	1.4	0
810	Biparatopic antibody BA7208/7125 effectively neutralizes SARS-CoV-2 variants including Omicron BA.1-BA.5. <i>Cell Discovery</i> , 2023, 9, .	3.1	11
811	Humoral immunity for durable control of SARS-CoV-2 and its variants. <i>Inflammation and Regeneration</i> , 2023, 43, .	1.5	6
812	Performance of the SureScreen Diagnostics COVID-19 antibody rapid test in comparison with three automated immunoassays.. <i>Diagnostic Microbiology and Infectious Disease</i> , 2023, , 115900.	0.8	0
814	Patient-reported outcomes after Tixagevimab and Cilgavimab pre-exposure prophylaxis among solid organ transplant recipients: Safety, effectiveness, and perceptions of risk. <i>Clinical Transplantation</i> , 2023, 37, .	0.8	4
815	Tixagevimab/Cilgavimab in SARS-CoV-2 Prophylaxis and Therapy: A Comprehensive Review of Clinical Experience. <i>Viruses</i> , 2023, 15, 118.	1.5	18
816	Neutralization sensitivity, fusogenicity, and infectivity of Omicron subvariants. <i>Genome Medicine</i> , 2022, 14, .	3.6	12
818	Neutralizing Efficacy of Encapsulin Nanoparticles against SARS-CoV2 Variants of Concern. <i>Viruses</i> , 2023, 15, 346.	1.5	4
819	A Spike-destructing human antibody effectively neutralizes Omicron-included SARS-CoV-2 variants with therapeutic efficacy. <i>PLoS Pathogens</i> , 2023, 19, e1011085.	2.1	5
820	Human neutralizing antibodies to cold linear epitopes and subdomain 1 of the SARS-CoV-2 spike glycoprotein. <i>Science Immunology</i> , 2023, 8, .	5.6	33
821	Safety, Tolerability and Pharmacokinetics of Half-Life Extended Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Monoclonal Antibodies AZD7442 (Tixagevimab-Cilgavimab) in Healthy Adults. <i>Journal of Infectious Diseases</i> , 2023, 227, 1153-1163.	1.9	4
822	CRISPR-Cas13d effectively targets SARS-CoV-2 variants, including Delta and Omicron, and inhibits viral infection. <i>MedComm</i> , 2023, 4, .	3.1	3

#	ARTICLE	IF	CITATIONS
823	State of the art in epitope mapping and opportunities in COVID-19. <i>Future Science OA</i> , 2023, 9, .	0.9	4
824	Antiviral neutralizing antibodies: from in vitro to in vivo activity. <i>Nature Reviews Immunology</i> , 2023, 23, 720-734.	10.6	8
825	A systematic study on the binding affinity of SARS-CoV-2 spike protein to antibodies. <i>AIMS Microbiology</i> , 2022, 8, 595-611.	1.0	2
826	TAT Nanobody Exerts Antiviral Effect against PRRSV In Vitro by Targeting Viral Nucleocapsid Protein. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1905.	1.8	1
827	Accelerated cell culture process development and characterization for cilgavimab/tixagevimab (AZD7442) for the prevention and treatment of COVID-19. <i>Biotechnology and Bioengineering</i> , 0, , .	1.7	1
828	The Role of Cyclodextrins in COVID-19 Therapy – A Literature Review. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2974.	1.8	8
830	Understanding the SARS-CoV-2 Virus Neutralizing Antibody Response: Lessons to Be Learned from HIV and Respiratory Syncytial Virus. <i>Viruses</i> , 2023, 15, 504.	1.5	0
831	Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause deadly disease. <i>Immunity</i> , 2023, 56, 669-686.e7.	6.6	43
832	Computational pipeline provides mechanistic understanding of Omicron variant of concern neutralizing engineered ACE2 receptor traps. <i>Structure</i> , 2023, 31, 253-264.e6.	1.6	3
833	Potent Therapeutic Strategies for COVID-19 with Single-Domain Antibody Immunoliposomes Neutralizing SARS-CoV-2 and Lip/cGAMP Enhancing Protective Immunity. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4068.	1.8	6
834	The Landscape of Neutralizing Monoclonal Antibodies (nAbs) for Treatment and Prevention of COVID-19. <i>Journal of Pharmaceutical Innovation</i> , 2023, 18, 1194-1212.	1.1	2
835	Lessons Learnt from COVID-19: Computational Strategies for Facing Present and Future Pandemics. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4401.	1.8	4
836	Structure-based design of oligomeric receptor-binding domain (RBD) recombinant proteins as potent vaccine candidates against SARS-CoV-2. <i>Human Vaccines and Immunotherapeutics</i> , 2023, 19, .	1.4	1
837	Pilot Study Results on Antibodies to the S- and N-Proteins of SARS-CoV-2 in Paired Sera from COVID-19 Patients with Varying Severity. <i>Antibodies</i> , 2023, 12, 19.	1.2	0
838	Novel bispecific human antibody platform specifically targeting a fully open spike conformation potently neutralizes multiple SARS-CoV-2 variants. <i>Antiviral Research</i> , 2023, 212, 105576.	1.9	5
839	Variants of SARS-CoV-2: Influences on the Vaccines™ Effectiveness and Possible Strategies to Overcome Their Consequences. <i>Medicina (Lithuania)</i> , 2023, 59, 507.	0.8	5
840	Molecular Characterization of AZD7442 (Tixagevimab-Cilgavimab) Neutralization of SARS-CoV-2 Omicron Subvariants. <i>Microbiology Spectrum</i> , 2023, 11, .	1.2	5
843	Enhanced neutralization escape to therapeutic monoclonal antibodies by SARS-CoV-2 omicron sub-lineages. <i>IScience</i> , 2023, 26, 106413.	1.9	13

#	ARTICLE	IF	CITATIONS
844	Application of Pseudotyped Viruses. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 45-60.	0.8	2
846	Antigenic mapping and functional characterization of human New World hantavirus neutralizing antibodies. <i>ELife</i> , 0, 12, .	2.8	9
847	Exploring the Potential of Broadly Neutralizing Antibodies for Treating SARS-CoV-2 Variants of Global Concern in 2023: A Comprehensive Clinical Review. <i>Cureus</i> , 2023, , .	0.2	1
848	mRNA vaccines and hybrid immunity use different B cell germlines against Omicron BA.4 and BA.5. <i>Nature Communications</i> , 2023, 14, .	5.8	4
849	Elicitation of potent neutralizing antibodies in obese mice by ISA 51-adjuvanted SARS-CoV-2 spike RBD-Fc vaccine. <i>Applied Microbiology and Biotechnology</i> , 2023, 107, 2983-2995.	1.7	1
850	Pre-clinical models to define correlates of protection for SARS-CoV-2. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	3
851	Nemacol is a small molecule inhibitor of <i>C. elegans</i> vesicular acetylcholine transporter with anthelmintic potential. <i>Nature Communications</i> , 2023, 14, .	5.8	3
852	Adjuvant-Free COVID-19 Vaccine with Glycoprotein Antigen Oxidized by Periodate Rapidly Elicits Potent Immune Responses. <i>ACS Chemical Biology</i> , 2023, 18, 915-923.	1.6	0
853	Modular adjuvant-free pan-HLA-DR-immunotargeting subunit vaccine against SARS-CoV-2 elicits broad sarbecovirus-neutralizing antibody responses. <i>Cell Reports</i> , 2023, 42, 112391.	2.9	1
854	Molecular Understanding of ACE-2 and HLA-Conferred Differential Susceptibility to COVID-19: Host-Directed Insights Opening New Windows in COVID-19 Therapeutics. <i>Journal of Clinical Medicine</i> , 2023, 12, 2645.	1.0	2
855	SARS-CoV-2 Omicron boosting induces de novo B cell response in humans. <i>Nature</i> , 2023, 617, 592-598.	13.7	49
856	Relationship between Vitamin D and Immunity in Older People with COVID-19. <i>International Journal of Environmental Research and Public Health</i> , 2023, 20, 5432.	1.2	1
859	Distinctive Dynamics and Functions of the CD4+CD25+FOXP3+ Regulatory T Cell Population in Patients with Severe and Mild COVID-19. <i>Journal of Immunology</i> , 2023, 210, 1687-1699.	0.4	4
860	SARS-CoV-2: Immunity, Challenges with Current Vaccines, and a Novel Perspective on Mucosal Vaccines. <i>Vaccines</i> , 2023, 11, 849.	2.1	12
883	Long-Term Vaccination and Treatment Strategies for COVID-19 Disease and Future Coronavirus Pandemics. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 27-49.	0.8	0
912	Vaccines and Drugs. <i>Springer Series in Biophysics</i> , 2023, , 887-896.	0.4	0
917	TO MARKET, TO MARKETâ€“2022: MACROMOLECULAR THERAPEUTICS. <i>Medicinal Chemistry Reviews</i> , 0, , 713-798.	0.1	0
932	Targeting bacterial polysaccharides with antibodies and vaccines. <i>Methods in Microbiology</i> , 2023, , .	0.4	0

#	ARTICLE	IF	CITATIONS
938	COVID-19 therapy directed against pathogenic mechanisms of severe acute respiratory syndrome coronavirus 2. , 2024, , 2697-2726.		0